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INTRODUCTION AND AIM OF THIS THESIS
1.1 General introduction 
Our word population is ageing rapidly, in particular in developing countries. In 
2025 the number of elderly people (over 60 years old) is estimated to be 1.2 
billion people. By that time 29.4% of the Dutch population will be older than 60 
years. The fastest growing group of elderly is the people aged over 80 years [1].
In 2002 the World Health Organization operationalised successful or healthy 
ageing in the concept of “Active Ageing” and defined it as the process of 
optimizing opportunities for health, participation and security in order to 
enhance quality of life as people age [1]. In this concept active does not merely 
refer to physical activity or participation in the workforce, but emphasizes the 
human right of elderly people to participate and contribute to their own family 
and social networks, as well as the nations they live in.
The active ageing concept also aims to increase healthy life expectation and 
maintain autonomy and independence. The most intriguing question with regard 
to ageing research is why some people age successfully and why others are 
burdened with chronic diseases and functional disability. Researchers aim to 
identify the candidate determinants associated with the preservation of vitality 
during a long life course.
1.2 Muscular ageing
Muscle mass declines with increasing age and low muscle mass is called 
sarcopenia. This term was first used by Rosenberg in 1988 and is derived from 
Latin, quite literally meaning “poverty of flesh”. In the last decade there is an 
astonishing increase in published research articles concerning causes of 
sarcopenia. Several international guidelines have now been published by 
different expert groups [2-5]. An important phenotype of declining muscle 
mass is loss of muscle strength or muscle weakness. Analogue to sarcopenia 
this muscle weakness is referred to as dynapenia [6, 7]. So far, researchers 
have established that sarcopenia and dynapenia are associated with a myriad 
of factors, such as inflammatory cytokines, hormones, and chronic diseases, as 
well as changes in muscle tissue architecture and vasculature [8, 9]. Both, 
sarcopenia and dynapenia are associated with detrimental outcome, such as 
mortality and disability [9, 10]. However, most studies focus on younger old 
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people and do not include oldest old people. Since oldest old are the fastest 
growing segment of the world population research needs to focus on the oldest 
old people.
1.3 Functional ability
Researchers and clinicians are becoming increasingly aware that functional 
ability is a marker of vitality. Disability in activities of daily living, slow walking 
and poor muscle strength are important markers of individual vulnerability to 
adverse events, such as aggravation of disability, hospitalization or even 
mortality [9, 11-20]. In clinical evaluation this functional phenotype could 
possibly be an important tool to assess prognosis of individual older patients 
[18-20]. But again, oldest old people are underrepresented in studies that focus 
on possible determinants of functional vitality and consequences of functional 
disability.
1.4 Aim and outline of this thesis
In this thesis the study of candidate determinants of muscular and functional 
vitality in a cohort of oldest old participants is described. All 599 participants 
of the Leiden 85-plus Study were 85 years old (1912 to 1914 birth-cohort) at 
inclusion. During the following 5 years, participants were visited at their place 
of residence by a research nurse who amongst others gathered data on health, 
cognition, mood, and functional ability. 
The first part of this thesis focuses on the functional phenotype with handgrip 
strength, gait speed and functional ability as the parameters of this functional 
phenotype. In chapters 2 and 3 the study of handgrip strength as a predictor of 
functional disability and changes in psychosocial health, and the association 
between handgrip strength and survival in oldest old people is presented. The 
prognostic value of walking speed and functional disability on survival in very 
old people is the focus of study in chapter 4. In chapter 5 the study of the 
relationship between functional disability and depressive symptoms is presented. 
And finally, the temporal association between cognitive performance and hand- 
 grip strength in oldest old people is described in chapter 6. 
1
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The second part of this thesis focuses on candidate determinants of muscle 
weakness in oldest old people. In chapter 7 the results of the study of the 
association between blood pressure and handgrip strength at baseline and 
declining handgrip strength over time are presented and the findings in the 
oldest old participants from the Leiden 85-plus Study is compared to those in 
middle-aged participants from the Leiden Longevity Study. In chapter 8 the 
association between insulin like growth factor-1 and handgrip strength is 
studied in oldest old and middle-aged participants from both Leiden based 
studies. Finally, in chapter 9, the relationship between innate production 
capacity of cytokines and handgrip strength decline is presented. 
In chapter 10 the findings and possible clinical implications and future research 
of all presented studies are summarized with a brief reflection on future 
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The functional phenotype as 
a predictor of health and survival

2
Handgrip strength as a predictor of 
functional, psychological and social health. 
A prospective population-based study 
among the oldest old
Taekema DG, Gussekloo J, Maier AB, Westendorp RG, de Craen AJ 




Background: Muscle wasting is associated with a detrimental outcome in older 
people. Muscle strength measurements could be useful as part of a clinical 
evaluation of oldest old patients to determine who are most at risk of accelerated 
decline in the near future.
Objective: To assess if handgrip strength predicts changes in functional, 
psychological, and social health among oldest old.
Design: Leiden 85-plus Study, a prospective population based follow-up study.
Subjects: 555 participants all aged 85 years at baseline. 
Methods: Handgrip strength was measured with a handgrip strength dynamo - 
meter. Functional, psychological, and social health were assessed annually. 
Baseline data on chronic diseases were obtained from the treating physician, 
pharmacist, electrocardiogram and blood sample analysis. 
Results: At age 85, lower handgrip strength was correlated with poorer scores 
in functional, psychological, and social health domains (all, P< 0.001). Lower 
baseline handgrip strength predicted an accelerated decline in ADL-ability 
and cognition (both, P≤ 0.001), but not in social health (P> 0.30). 
Conclusion: Poor handgrip strength predicts accelerated dependency in ADL 
and cognitive decline in oldest old. Measuring handgrip strength could be a 
useful instrument in geriatric practice to identify those oldest old patients at 
risk for this accelerated decline. 
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22.2 Introduction
Muscle wasting is a dominant feature of old age, and is commonly referred to 
as sarcopenia. Estimates of the prevalence of sarcopenia range depending on 
the definition from 18% to over 60% in the general population of the oldest old 
[1]. Due to a rapid growth of the number of oldest old in our societies, sarcopenia 
will become a common health problem [1]. 
Muscle wasting is associated with detrimental outcome in the elderly, such as 
disability and mortality [2]. Several recent cross-sectional studies have shown 
associations between muscle strength and physical fitness, disability, or 
cognition [3-6]. A number of prospective studies have described the association 
of handgrip strength and health decline in the elderly, predominantly 
describing its association with functional disability [7-12] and mortality [13, 
14]. A limited number of studies report on the associations between muscle 
strength and cognition [15-17]. 
All these associations raise the question about the value of muscle strength as 
a potential predictor of declining health in the oldest old. Muscle strength 
measurements could be useful as part of a clinical evaluation of the oldest old 
patients in determining which patients are most at risk of accelerated decline 
in the near future. Therefore we have studied the impact of muscle weakness 
on three health domains, functional, psychological and social health. Handgrip 
strength was used as a proxy for muscle strength in this study [3].
2.3 Methods
2.3.1 Participants and procedures
The Leiden 85-plus Study is a community-based prospective follow-up study of 
inhabitants of the city of Leiden, the Netherlands. Enrolment took place 
between 1997 and 1999. All inhabitants, including nursing home residents, 
who reached the age of 85 were eligible to participate. There were no selection 
criteria on health or demographic characteristics [18]. In total 599 persons 
participated, 87% of all eligible inhabitants. At baseline, a research nurse 
visited participants at their place of residence. During these visits, socio- 
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demographic characteristics including gender, marital status and living situation 
were recorded, performance tests were conducted, blood samples collected, 
and an electrocardiogram (ECG) was recorded. The medical history was 
obtained from the general practitioner or nursing home physician. Follow up 
visits were performed annually. The Medical Ethical Committee of the Leiden 
University Medical Center approved the study. All participants gave informed 
consent. In case of severe cognitive impairment, a guardian gave informed 
consent. 
2.3.2 Handgrip strength
At ages 85 and 89, handgrip strength was measured with a Jamar hand 
dynamometer (Sammons Preston Inc, Bolingbrook, IL). The participant was 
asked to stand up and hold the dynamometer in the dominant hand with the 
arm parallel to the body without squeezing the arm against the body. The 
width of the handle was adjusted to the size of the hand to make sure that the 
middle phalanx rested on the inner handle. The participant was allowed to 
perform one test trial. After this, three trials followed and the best score was 
used for analysis. Handgrip strength was expressed in kilograms (Kg). Only 
handgrip strength measurements that were assessed as reliable by the 
research nurse were included in the analysis. The research nurse judged the 
effort according to the following criteria: refusal of participation, physical 
impairment, cognitive impairment, inability to follow the instructions, and 
technical difficulties.
2.3.3 Items of functional health 
Competence in daily functioning was measured with the Groningen Activity 
Restriction Scale (GARS) [19]. The GARS is a questionnaire that assesses 
disabilities in competence in the area of nine basic activities of daily living 
(ADL) and nine instrumental activities of daily living (IADL). A sum score was 
calculated separately for ADL and IADL. Hence, each sum score ranged from 
nine (competent in all activities) to 36 (unable to perform any activity without 
help). Walking speed was assessed with a standardized six-meter walking test 
as used in other longitudinal ageing studies [20]. Participants were requested 
to walk three meters back and forth as quickly as possible. The use of a walking 
aid was allowed during this test. The time for the walking test was measured 
in seconds. 
23
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22.3.4 Items of psychological health 
Cognitive functioning was measured with the Mini Mental State Examination 
(MMSE) [21]. The 15-item Geriatric Depression Scale (GDS-15) was used as a 
screening instrument for depression. [22]. As the validity and reliability of 
the GDS-15 may be reduced in subjects with impaired cognitive function, 
this questionnaire was restricted to those with MMSE scores above 18 points 
(n= 482) [23-24]. 
2.3.5 Items of social health
Social functioning was measured with the Time Spending Pattern questionnaire 
(TSP). The TSP lists involvement in social and leisure activities leading to a 
sum-score for these activities [25]. The questionnaire consists of 23 items (e.g. 
bathing a spouse, cycling, gardening, reading a book, or watching television) 
scored from 0 (no activities) to 4 (participating in activity on a daily basis). 
Feelings of loneliness were annually assessed by the Loneliness Scale [26], an 
11-item questionnaire especially developed for use in elderly populations. 
Scale scores range from 0 (absence of loneliness) to 11 (severe loneliness). The 
Loneliness Scale was also restricted to those with MMSE scores above 18 
points.
2.3.6 Potential confounders
Data on common chronic diseases were obtained from the general practitioner, 
pharmacist’s records, electrocardiogram (ECG), and blood sample analysis [27]. 
Chronic diseases included stroke, angina pectoris, myocardial infarction, 
intermittent claudication, peripheral arterial surgery, diabetes mellitus, 
obstructive pulmonary disease, malignancy, and arthritis. Multi-morbidity 
was defined as the sum score of these somatic diseases. 
2.3.7 Statistical analysis
Baseline cross-sectional associations at age 85 were assessed between tertiles 
of handgrip strength and items of health, using ANOVA (Analysis of variance). 
Handgrip strength was ranked and divided into tertiles for men and women 
separately.
The prospective association between handgrip strength and the items of 
health was analysed with linear mixed models. The flexibility of mixed models 
makes them the preferred choice for the analysis of repeated-measures data 
24
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[28]. The used models included estimates for “handgrip strength”, “time”, and 
“handgrip strength*time”. The estimate for “handgrip strength” indicates the 
baseline association between handgrip strength and health item scores 
(presented in Table 3 as “baseline difference”). This estimate indicates the 
change in health items per kilogram increase in handgrip strength. The 
estimate for “time” indicates the annual change in performance for those 
participants with mean handgrip strength levels (presented in Table 3 as 
“annual change”). The estimate for “handgrip strength*time” indicates the 
accelerated annual decline in health items per kilogram decrease of handgrip 
strength at baseline (presented in Table 3 as “accelerated decline”). All estimates 
were adjusted for gender, height, weight, and income. Estimates were standardized 
per kilogramme change of handgrip strength by using the formula: (individual 
handgrip strength - mean handgrip strength in study population). 




Reliable scores for handgrip strength were available for 555 (92.6 %) participants 
at age 85. At baseline there were 44 non-completed handgrip strength measure - 
ments due to refusal to participate (n=3), physical impairment (n= 17), cognitive 
impairment (n=9), inability to follow instructions (n= 5) and other reasons 
(n= 10). There were 73 (12.9 %) participants with an MMSE score ≤ 18 points, 
being indicative of cognitive impairment. Depressive symptoms (GDS score 
≥ 4 points) were present in 114 (20.5%) of the participants. The other baseline 
characteristics of the study population are shown in table 1. 
2.4.2 Functional, psychological, and social health domain
The cross-sectional analyses at age 85 of functional, psychological, and social 
items of health are shown in table 2 for each tertile of handgrip strength. 
Lower handgrip strength was significantly correlated with poorer health item 
scores at baseline (Table 2, all P≤ 0.03). 
25
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2
To analyze the prospective association between baseline handgrip strength 
and changes in the various health domains we used linear mixed models (Table 
3). In line with the cross-sectional results we confirmed the association 
between handgrip strength and health item scores at baseline as indicated by 
‘baseline difference’. Over time all health items, except loneliness, declined as 
indicated by the estimate “annual change”. Finally, we assessed if lower 
handgrip strength at baseline predicted an accelerated decline in the health 
domains as assessed by the estimate “accelerated decline”. Where such an 
estimate is significant, this indicates a predictive relationship in the model. 
Lower handgrip strength predicted an accelerated decline in ADL-disability in 
Table 1  Characteristics of participants (N=555)  at baseline (85 years)
Men (%) 194 (35.0)
Widowed (%) 314 (56.6)
Living arrangements 
           Independent (%) 319 (57.5)
           Sheltered (%) 156 (28.1)
           Institutionalized (%) 80 (14.4)
General health
≥ 3 chronic diseases * (%) 135 (24.3)
Body Mass Index < 20 (%) 24 (4.5)
Functional health domain (median, ITR)†
ADL disability (GARS, points)‡ 10 (9.0-11.0)
IADL disability (GARS, points)‡ 17 (13.8-22.0)
Walking speed (6 meter walking test, sec)§ 11.6 (9.4-14.2)
Psychological health domain (median, ITR)
Cognition (MMSE, points)** 26 (24-28)
Depression (GDS, points)†† 2 (1-3)
Social health domain (median, ITR)
Time spending pattern (TSP, points)‡‡ 48 (43-51)
Loneliness (de Jong Gierveld scale, points)§§ 1 (0-2)
*  Chronic diseases included stroke, angina pectoris, myocardial infarction, intermittent claudication, 
peripheral arterial surgery, diabetes mellitus, obstructive pulmonary disease, malignancy, and 
arthritis; † ITR = intertertile range; ‡ GARS = Groningen Activity Restriction Scale, possible scores 
range from 9-36 points (best to worst); § Walking speed, scores ranged from 4.16 to 76.47 seconds 
(best to worst); ** MMSE = Mini Mental State Examination, possible scores range from 0-30 points 
(worst to best); †† GDS-15 = Geriatric Depression Scale 15 items, possible scores range from 0-15 
points (best to worst); ‡‡TSP = Time Spending Pattern questionnaire, possible scores range from 
0-92 points (worst to best); §§ Loneliness scale, possible scores range from 0-11 points (best to worst).
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the functional health domain (0.02 points increase in GARS score per kg loss of 
handgrip strength, P≤ 0.001) and cognition in the psychological health domain 
(0.01 points decline in MMSE score per kg loss of handgrip strength, P= 0.001), 
but not in other items of health (all P> 0.30). Additional adjustments for 
baseline MMSE and GDS scores did not change the prospective results of the 
functional health items. The prospective results of the psychological health 
items did not change after adjustment for baseline scores of ADL disability, 
IADL disability and walking speed. The results of the social health items were 






















Domain n = 194 n = 177 n = 184
Functional health 
ADL-disability‡ (points) 10.2 (0.2) 11.1 (0.2) 14.1 (0.5) < 0.001
IADL-disability‡ 
(points)
21.8 (0.8) 18.3 (0.5) 23.6 (0.7) < 0.001
Walking speed (sec)§ 10.9 (0.7) 14.8 (0.7) 18.8 (1.1) < 0.001
Psychological health 
Cognition** (points) 26.3 (0.3) 25.4 (0.3) 22.3 (0.5) < 0.001




50.3 (0.5) 48.3 (0.5) 44.3 (0.5) < 0.001
Loneliness§§ (points) 1.6 (0.2) 1.5 (0.2) 2.1 (0.2) 0.03 
* Data presented as mean (SE). Handgrip strength were ranked and divided into tertiles for men and 
women separately; † ANOVA;  ‡ Groningen Activity Restriction Scale, possible scores range from 
9-36 points (best to worst) ; §  Six-meter walking test, scores ranged from 4.16 to 76.47 seconds 
(best to worst); ** Mini Mental State Examination, possible scores range from 0 -30 points  ( worst to 
best); †† GDS-15 = Geriatric Depression Scale 15 items, possible scores range from 0-15 points (best 
to worst); ‡‡ Time Spending Pattern questionnaire,  possible scores range from 0-92 points (worst 
to best); §§ De Jong Gierveld Loneliness scale, possible scores range from 0-11 points (best to worst).
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The aim of the present study was to explore if handgrip strength predicts 
decline in functional, psychological, and social health in the oldest old. Our 
findings show that lower handgrip strength predicted an accelerated decline 
in ADL-disability and cognition, and thus contributes to increasing dependency 
in old age. 
To our knowledge our study is the first to report on the prospective associations 
between handgrip strength and three health domains in a cohort of oldest old 
participants. A number of other studies have reported on prospective associations 
between handgrip strength and functional ability, or cognition in the elderly, 
but the mean age of participants in these prospective studies was younger and 
none of these included all three health domains [7- 12, 15– 17]. Some of these 
studies were limited to men [7, 8] or women [12, 13]. 
We confirmed the predictive value of handgrip strength in the functional 
health domain in oldest old participants. No predictive association was found 
between handgrip strength and IADL disability, which had been shown to be a 
predictor in Japanese community dwelling elderly in participants aged 65 
years and older [9]. For walking speed we could not confirm a predictive value 
of handgrip strength, which were associated with each other in a comprehensive 
cross-sectional study [3]. 
For the association between muscle strength and functional health, one would 
expect that interventions aimed at improving muscle strength are beneficial. A 
recent review [29] has assessed the effect of resistance training on physical 
functioning in subjects over 60 years old. High intensity strength training, 
three times a week, significantly improved muscle strength, and was associated 
with improvement in physical ability.
Our finding that low handgrip strength predicts accelerated cognitive decline 
has been reported by others, but again in younger study participants [15–17]. 
Changes in handgrip strength did not predict changes in depression, possibly 
because of a process of psychological adaptation during ageing in elderly 
people [30]. 
In the social health domain no predictive association was found with the item 
loneliness. This might be explained by the fact that the need for care results in 
regular contact with caregivers thereby stimulating psychological well being 
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2as suggested by a cross-sectional Scandinavian study among elderly nursing 
home residents [31]. 
This study has several strengths key to studying consequences of sarcopenia 
in elderly people. The Leiden 85-plus Study is a longitudinal population based 
cohort study with extensive measures for health and functioning. Therefore 
the results can be generalized to the western population of oldest old. Furthermore 
the longitudinal design with repeated measurements of diverse items of health 
allowed us to demonstrate a temporal association.
A possible weakness of our study could be that our participants appear to be 
relatively fit. For very frail elderly people, measuring handgrip strength might 
be difficult and the results could not be applicable to this group. But, only 44 (7.3 
%) measurements of handgrip strength were excluded from our study because 
these were deemed unreliable. Of which, 31 (5.2 %) were the result of physical or 
cognitive impairment. We don’t know if our participants are fitter compared to 
other oldest old. Comparison of participant characteristics of the Leiden 85 plus 
Study with other prospective studies on ageing is difficult, because of age 
differences and different methodology. The Newcastle 85 plus Study started in 
2006 [32] and is comparable in design to the Leiden 85 plus Study. The charac-
teristics of the subjects from the Newcastle pilot study are similar to our study 
participants with regard to living arrangements, cognitive ability and depressive 
symptoms [33]. Another weakness of the study could be that the questionnaires 
on depression and loneliness were limited to those participants without cognitive 
decline which could have underestimated the associations between handgrip 
strength and the psychological indicators. However, only 73 (13%) of the participants 
were excluded due to an MMSE score of 18 points or lower. One could also argue 
that the chosen health domains are indirectly related to one another, however 
further adjustment of the linear mixed model for this possible confounding did 
not change the results. 
Functional measurements, as walking or gait speed, chair stand test and balance, 
have also been shown to predict functional limitations of the lower body [12, 
20, 34], and cognition [35] in older subjects. As yet it is unclear whether muscle 
strength or functional measurements is the stronger predictor, and which 
causal pathways are involved. An advantage of handgrip strength could be 
that it is easy to use in clinical practice. 
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We conclude that poor handgrip strength is a predictor of accelerated dependency 
in ADL and cognitive decline in oldest old. Based on these findings, we conclude 
that measuring handgrip strength could be a useful instrument in geriatric 
clinical practice to identify those oldest old patients at risk for accelerated 
decline in ADL ability and cognition. 
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Handgrip strength and 
mortality in the oldest old population: 
the Leiden 85-plus Study
Ling CH, Taekema D, de Craen AJ, Gussekloo J, Westendorp RG, Maier AB 




Background: Poor muscular strength has been shown to be associated with 
increased morbidity and mortality in diverse samples of middle-aged and 
elderly people. However, the oldest old population (i.e., over 85 years) is under-
represented in such studies. Our objective was to assess the association between 
muscular strength and mortality in the oldest old population.
Methods: We included 555 participants (65% women) from the Leiden 85-plus 
Study, a prospective population-based study of all 85 year-old inhabitants of 
Leiden, The Netherlands. We measured the handgrip strength of participants 
at baseline and again at age 89 years. We collected baseline data on comorbidities, 
functional status, levels of physical activity, and adjusted for possible confounders. 
During the follow-up period, we collected data on mortality. 
Results: During a follow-up period of 9.5 years (range 8.5–10.5 years), 444 
(80%) participants died. Risk for all-cause mortality was elevated among 
participants in the lowest tertile of handgrip strength at age 85 years (hazard 
ratio [HR] 1.35, 95% confidence interval [CI] 1.00–1.82, p= 0.047) and the 
lowest two tertiles of handgrip strength at age 89 years (HR 2.04, CI 1.24–3.35, 
p= 0.005 and HR 1.73, CI 1.11–2.70, p= 0.016). We also observed significantly 
increased mortality among participants in the tertile with the highest relative 
loss of handgrip strength over four years (HR 1.72, CI 1.07–2.77, p= 0.026).
Interpretation: Handgrip strength, a surrogate measurement of overall muscular 
strength, is a predictor of all-cause mortality in the oldest old population and 
may serve as a convenient tool for prognostication of mortality risk among 
elderly people.
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3.2 Introduction
The fastest growing segment of the elderly population is the group older than 
85 years, which is classified as the oldest old age group [1, 2]. The average rate 
of growth of this group is reported to be 3.8% annually at a global level. By 
2050, the oldest old age group will account for one-fifth of all older persons [2]. 
Inactivity is a major problem in this age group, owing to an increased prevalence 
of medical comorbidities and physical disability with age. Age-related stereo- 
types and misconceptions (e.g., that older people are invariably unhealthy), 
coupled with a perceived lack of benefits provided by physical activity, can 
also represent obstacles to exercise among the oldest old population. 
The predisposing influence of a sedentary lifestyle on age-related cardiometa-
bolic diseases (i.e., obesity, type 2 diabetes mellitus, hypertension and coronary 
artery disease) is well established. Evidence of the protective effects of physical 
activity against certain cancers, falls and mental health problems is accumulating 
[3, 4]. Lack of exercise is also a significant risk factor for sarcopenia [5, 6], a 
progressive loss of skeletal muscle mass and strength with aging [7]. Sarcopenia 
is highly prevalent among those aged 80 years and older, with reported rates 
exceeding 50% [8]. Reduced muscular strength is associated in turn with 
outcomes such as physical disability [9, 10], cognitive decline [11] and mortality 
[12, 13].
Handgrip strength, a simple bedside tool, has been shown to be a valid surrogate 
measurement of overall muscular strength [14, 15]. A recent systematic review 
has shown that low handgrip strength is associated consistently with premature 
mortality, disability and other health-related complications among various 
samples of middle-aged and older people [16]. 
Despite its prognostic value, handgrip dynamometry is rarely used in routine 
geriatric assessment. Epidemiologic studies evaluating the relation in the 
population of the oldest old are also lacking. We tested the association between 
handgrip strength and mortality in a prospective population-based study of 
the oldest old age group. We obtained approval for our study from the Medical 
Ethical Committee of the Leiden University Medical Center, and informed 





We obtained data from the prospective population-based Leiden 85-plus 
study, which involved all 85-year-old inhabitants of Leiden, The Netherlands. 
A total of 599 participants had been enrolled in the study (with a response rate 
of 87%) between September 1997 and September 1999. No selection criteria 
had been imposed for health status or demographic characteristics. Participants 
had been visited annually at their homes, where face-to-face interviews, blood 
samples and various functional tests were performed. Further information on 
the design of the Leiden 85-plus study and characteristics of its cohort is 
published elsewhere [17]. In our analysis, we included 555 participants from 
whom we obtained reliable handgrip strength measurement at baseline (i.e., age 
85 years). We performed a repeat measurement of handgrip strength in a total of 
304 participants (55%) at 89 years of age.
3.3.2 Strength assessment 
We measured handgrip strength to the nearest kilogram of each participant’s 
dominant hand using a Jamar hand dynamometer (Sammons Preston Inc., 
Bolingbrook, IL). We performed the measurement with the participant in an 
upright position and with the arm of the measured hand unsupported and 
parallel to the body. The width of the dynamometer’s handle was adjusted to 
each participant’s hand size so that the middle phalanges rested on the inner 
handle. We instructed participants to exert maximal force. For each participant, 
we allowed one test trial, then took three test measurements. We used the 
highest of the three recorded measurements in our analysis. We used the same 
protocol for each participant’s follow-up visit at age 89 years. 
To calculate the relative change in handgrip strength over four years, we 
divided the difference between the handgrip strength measurements taken at 
ages 85 and 89 years by the baseline value and multiplied the result by 100. We 
stratified the measurements of handgrip strength at ages 85 and 89 years and 
relative change in handgrip strength over four years into tertiles for men and 
women separately. We then created sex-specific tertiles by combining categories 
of tertiles for men and for women.
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3.3.3 Possible confounders
We considered sex, anthropometric data, comorbidities, total number of 
prescription medications and smoking status to be potential confounders of an 
association between handgrip strength and mortality, and included these data 
in our analysis. Our measurement of body surface area was based on the 
Mosteller formula [20]. We recorded data on seven medical comorbidities, 
which were cardiovascular disease (comprising ischemic heart disease, cere-
brovascular disease and peripheral vascular disease), hypertension, diabetes 
mellitus,chronic obstructive pulmonary disease, neoplasm, Parkinson disease, 
and arthritis (comprising osteoarthritis, rheumatoid arthritis and polymyalgia 
rheumatica). 
We also considered scores on the Mini-Mental State Examination, Geriatric 
Depression Scale, Activities of Daily Living disability scale, Instrumental 
Activities of Daily Living disability scale and level of physical activity to 
represent potential confounders. We measured scores on the Activities of 
Daily Living and Instrumental Activities of Daily Living disability scales using 
the Groningen Activity Restriction Scale, where a score of 18 indicates not 
disabled and a score of 72 indicates severely disabled [18]. 
To measure levels of physical exercise beyond routine daily physical activity, 
we used four items from the Time-Spending Patterns questionnaire [19] 
related to walking for fun, cycling for fun, exercising (either alone or in groups) 
or other physical activity, and working in the garden. We scored each item 
from 0 (no activity) to 4 (daily participation in the activity), then added these 
values together to reach a sum score of physical activity level for each 
participant. We also collected data on the living arrangements of participants 
(i.e., independent or in residential care). We did not include these data in the 
final model because living arrangement is determined primarily by factors 
already included in the multivariate model (i.e., functional abilities, cognition, 
comorbidities).
3.3.4 Follow-up
We collected data on mortality among participants until February 2008. The 
range of the follow-up period was 8.5–10.5 years. Information on follow-up for 
mortality was available for the whole study population. We obtained dates of 
deaths from the Dutch civic registry and specific data on causes of death from 
Statistics Netherlands, which assigns codes for all national death certificates 
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according to the International Classification of Diseases and Related Disorders, 
10th revision (ICD-10). Causes of death were divided into cardiovascular 
causes (ICD-10 codes I00-I99) and non-cardiovascular causes(all other ICD-10 
codes). Cardiovascular causes were further classified into coronary artery 
disease, stroke and others. The non-cardiovascular causes were classified into 
infection with or without sepsis, pneumonia, neoplasm and others. Pneumonia 
was included because it is one of the major causes of death among elderly 
people.
3.3.5 Statistical analysis
Continuous variables with Gaussian distribution are presented as mean 
(standard deviation [SD]) and those with non-Gaussian distribution as median 
(interquartile range [IQR]). We used a paired t test to compare two groups of 
paired data that were of Gaussian distribution. To adjust for difference in 
physical capacity between men and women, we created sex-specific tertiles of 
handgrip strength, which were combined categories of tertiles for men and for 
women. We used a χ2 test to compare categoric variables and a Kruskal–Wallis 
test to compare non-normally distributed variables between the tertiles of 
handgrip strength. 
We applied Kaplan–Meier curves to display survival according to tertiles of 
handgrip strength for participants at age 85 years and for those at age 89 
years, and for the relative change in handgrip strength over four years. We 
assessed the analysis of survival using Cox regression analyses. We adjusted 
the hazard ratios (HR) of mortality for potential confounders using baseline 
data reflecting presence of comorbidities, total number of prescription 
medications and smoking status, and data collected at baseline or age 89 years 
for body surface area, for scores on the Mini-Mental State Examination, the 
Geriatric Depression Scale, the Activities of Daily Living disability scale and 
the Instrumental Activities of Daily Living disability scale, and for level of 
physical activity. 
We corrected the HRs for relative change in handgrip strength using data on 
comorbidities, total number of prescription medications and smoking status at 
baseline, on body surface area at age 89 years, and on absolute change in scores 
on the Mini-Mental State Examination, Geriatric Depression Scale, Activities of 
Daily Living disability scale, Instrumental Activities of Daily Living disability 
scale, and in level of physical activity over four years. In addition, we analyzed 
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handgrip strength as a continuous variable in the multivariable model with 
adjustment for the above variables. For all fully adjusted models, we calculated 
the coefficient of determination (i.e., R2) using the method of Nagelkerke [21]. 
We considered a two-tailed p-value of less than 0.05 to be significant.
3.4 Results
The baseline clinical characteristics of the 555 participants in the study according 
to tertile of handgrip strength are presented in Table 1. Cardio vascular disease 
was the most prevalent comorbidity. At baseline, the median Mini-Mental State 
Examination score was 26, with evidence of severe cognitive impairment (i.e., 
score < 19) in 13% of participants. At age 89 years, impairment was evident in 
25%. The median score on the Geriatric Depression Scale at baseline was 2 
(IQR 1–3), with evidence of depression (i.e., score ≥ 4) in 113 participants, who 
represented 23.4% of those without severe cognitive impairment at baseline 
compared with 27.7% at age 89 years. At baseline, the median score on the 
Activities of Daily Living disability scale was 10 (IQR 9–13); on the Instrumental 
Activities of Daily Living disability scale it was 17 (IQR 12–25); and on the 
Groningen Activity Restriction Scale it was 27 (IQR 21–37). The median sum 
scores for level of physical activity at baseline was 7 (IQR 5–8). 
Lower handgrip strength was significantly related to higher rates of cardio-
vascular disease (P = 0.031) but not to other comorbidities. Lower handgrip 
strength was also significantly associated (P < 0.001) with lower scores on the 
Mini-Mental State Examination and with higher scores on the Geriatric 
Depression Scale, the Activities of Daily Living disability scale and the 
Instrumental Activities of Daily Living disability scale, and, finally, with a 
lower score for level of physical activity. We also observed a significant 
difference in living arrangement among participants in different tertiles of 
handgrip strength, with a greater proportion of participants with lower 
handgrip strength living in residential care. 
Anthropometric data and measurements of handgrip strength collected at 
ages 85 and 89 years and stratified by sex are presented in Table 2. Of the 555 
participants, 357 (64.3%) lived to age 89 years. Measurements of handgrip 
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Table 1   Clinical characteristics at baseline (age 85 years) of the study 
population by sex- specific tertile of handgrip strength 









Sex, female, % 65.0 64.7 64.4 66.0 0.943
Living arrangement, % <0.001
Independent living 85.9 73.9 88.7 94.8
Residential care 14.1 26.1 11.3 5.2
Smoking status, % 0.533
Non-smoker 50.4 55.2 46.3 49.5
Previous smoker 34.1 30.1 36.7 35.6
Current-smoker 15.5 14.8 16.9 14.9
Comorbidity, %
Cardiovascular disease 62.5 66.8 66.1 55.2 0.031
Hypertension 38.7 33.2 41.8 41.2 0.163
Diabetes mellitus 15.3 18.5 15.8 11.9 0.197
COPD 11.7 13.0 10.7 11.3 0.777
History of neoplasm 17.9 18.8 14.1 20.6 0.943
Parkinson’s disease 2.0 2.2 1.7 2.1 0.249
Arthritis 32.7 30.4 35.8 32.1 0.542
Medications, no., median (IQR) † 2 (1-4) 2 (1-4) 2 (1-4) 2 (1-4) 0.074
Mental status, median (IQR)
MMSE 26 (23-28) 24 (18-27) 27 (24-28) 27 (25-29) <0.001
GDS-15 2 (1-3) 2 (1-4) ‡ 2 (1-3) § 1 (0-2) � <0.001
Functional status, median (IQR)
ADL disability score¶ 10 (9-13) 11 (9-17) 10 (9-12) 9 (9-10) <0.001
IADL disability score¶ 17 (12-25) 24 (16-32) 17 (13-22) 14 (10-19) <0.001
GARS¶ 27 (21-37) 36 (25-48) 27 (22-34) 24 (20-30) <0.001
PAS, median (IQR) ** 7 (5-8) 6 (4-8) 7 (4-8) 7 (6-9) <0.001
* p-value between gender specific handgrip strength tertiles by χ2 and Kruskal-Wallis tests for 
categorical and continuous variables respectively. †N= 526; ‡N= 135; §N= 163; � N= 186; ¶ N= 553; 
** N= 538. Reference range for gender specifc handgrip strength tertiles: low (female: 1-16 kg; 
male: 10-27 kg), middle (female: 17-20 kg; male: 28-33 kg), high (female: 21-31 kg; male: 34-54 kg). 
Cardiovascular disease includes ischemic heart disease, cerebrovascular disease and peripheral 
vascular disease. Arthritis includes osteoarthritis, rheumatoid arthritis and polymyalgia 
rheumatica. IQR = interquartile range.  MMSE=Mini-Mental State Examination (score range 0-30); 
GDS-15=Geriatric Depression Scale-15 (score range 0-15); ADL=activities of daily living (score range 
9-36); IADL=instrumental activities of daily living (score range 9-36); GARS=Groningen Activity 
Restriction Scale (score range 18-72); PAS= physical activity score (sum score of 4 physically active 
items from the Time Spending Pattern questionnaire, score range 0-16).
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strength were not available for 53 participants at age 89 years, most of whom 
withdrew from the study. Participants who were lost to follow-up measurement 
of handgrip strength did not differ significantly (P≥ 0.083) from the group as 
a whole in comorbidities, cognitive status and functional status at baseline. 
Handgrip strength among men was consistently higher than among women, 
both at baseline (30.6 kg [SD 8.2] v.18.7 kg [SD 5.5], p< 0.001) and at age 89 
years (25.6 kg [SD 7.8] v. 16.4 kg [SD 5.0], P< 0.001). Among both women and 
men, handgrip strength declined significantly from age 85 to 89 years, with 
an average loss of strength of 1.53 kg per year among men and 0.85 kg per 
year among women. However, no significant difference was evident between 
men and women in relative loss of handgrip strength over four years (–19.2% 
[SD 16.7] v. –15.9% [SD 22.4], P = 0.156). 
During a follow-up period of 9.5 years (range 8.5–10.5 years), 444 deaths 
(80%) occurred, with a greater proportion of deaths among men, at 88.1%, 
compared with women, at 75.6% (P< 0.001). Mean lifespan was 89.7 years (SD 
3.0) among men and 91.0 years (SD 3.0) among women. Of the deaths, 36.7% 
had cardiovascular causes (coronary artery disease 30.1%, stroke 26.4%, 
unspecified 43.5%). Of the deaths that were attributed to noncardiovascular 
causes, 28.8% were caused by neoplasm, 10.0% were caused by infection (of 
which 85.7% were related to pneumonia) and 61.2% were unspecified. 
Kaplan–Meier cumulative survival curves for all-cause mortality are presented 
in Figure 1. The curves are stratified by sex-specific tertile of handgrip strength 
at baseline, of handgrip strength at 89 years of age, and of relative change in 
handgrip strength over four years. The unadjusted and adjusted HRs for 
all-cause mortality are shown in Table 3. The HRs are stratified by tertile of 
handgrip strength at age 85 years, handgrip strength at age 89 years and relative 
change in handgrip strength from age 85 to 89 years. 
After adjusting for possible confounders, we found a significant elevation in 
risk for all-cause mortality among participants in the lowest tertile of handgrip 
strength at age 85 years (HR 1.35, 95% CI 1.00–1.82, P= 0.047) and the lowest 
two tertiles of handgrip strength at age 89 years (HR 2.04, 95% CI 1.24–3.35, 
P= 0.005 and HR 1.73, CI 1.11–2.70, P= 0.016), with greater HRs in the latter age 
group. We also observed a significantly increased mortality among participants in 
the tertile with the highest relative loss of handgrip strength over four years 
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(HR 1.72, CI 1.07–2.77, P= 0.026). The coefficients of determination were 0.18 
for handgrip strength at baseline, 0.27 for handgrip strength at age 89 years 
and 0.23 for relative loss of handgrip strength. Baseline handgrip strength, 
handgrip strength at age 89 years and relative loss of handgrip strength were 
not associated with increased risk for mortality from specific causes. 
Figure 1   Kaplan-Meier cumulative survival curves for all-cause mortality 
based on sex-specific tertile of handgrip strength (A) at age  
85 years, (B) at age 89 years and (C) by relative change in handgrip 
strength over 4 years. The highest tertile of relative change in 
handgrip strength refers to the tertile with the lowest loss of 
handgrip strength over four years.
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When we analyzed handgrip strength as a continuous variable in our multi -
variable analysis, we found that, for each 5-kg reduction in handgrip strength, 
an increase in risk for all-cause mortality occurred at age 85 years (HR 1.11, CI 
1.01–1.23, P= 0.040) and at age 89 years (HR 1.24, CI 1.04–1.48, P= 0.019). 
Similarly, we observed an increase in risk for all-cause mortality for every 
additional 5% loss of relative handgrip strength (HR 1.06, CI 1.01–1.12, 
P= 0.033).
3.5 Discussion
Our results show that low handgrip strength at ages 85 and 89 years, and a 
greater decline in strength over time, are associated with increased all-cause 
mortality. Our findings also suggest a greater association between handgrip 
strength and mortality with increasing age. 
The mechanisms underlying the association between muscle strength and 
mortality are not well understood. We were unable to ascertain whether the 
relation between muscle strength and mortality is direct or whether muscular 
strength is a surrogate marker of other factors underlying mortality. Future 
studies of interventions like resistance training, which has been shown to 
be efficacious in preserving muscular strength [23] could show whether 
maintenance of muscular strength translates into a reduction in mortality 
among weak elderly people. Our finding of increased risk for mortality among 
weak elderly people suggests that family physicians need to pay special 
attention to general prevention-related measures in these patients. 
Our study had limitations. Our assessment of comorbidities was limited to 
common chronic diseases. We did not address severity of disease, which could 
affect probability of survival. Lower handgrip strength can be an indicator of 
subclinical diseases that affect mortality. In addition, we were unable to adjust 
for the interim development or progression of comorbidities. We did not 
observe an association between handgrip strength and cause-specific mortality, 
although several previous studies have linked poorer grip strength to 
mortality resulting from cardiovascular diseases [24, 25], respiratory diseases 
[25] and cancer [24]. This finding may be explained by the relatively small 
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number of deaths from each specific cause in our study. The values for handgrip 
strength in our study population were comparable to other population-based 
studies involving older adults of similar ages [26]. However, handgrip strength 
has been shown to be associated with ethnicity, and is weaker among Asian 
populations compared with Western [27]. Given that our study was based on a 
homogenous Dutch population, the cutoff threshold for handgrip strength, 
below which is an increased risk for mortality, may not be generalizable to all 
elderly populations. 
Our findings have substantial implications for care of a growing elderly 
population. Application of handgrip dynamometry as a screening tool in a mul-
tidimensional geriatric assessment may help identify older people at risk for 
disability and holds potential for use in prognostication of survival among 
elderly people. Further studies exploring factors that contribute to loss of 
muscular strength could provide valuable information toward the development 
of strategies for preserving muscular strength with advancing age.
3.6 Acknowledgments 
We thank Carolien Wijsman for her stimulating discussion and data analysis.
3.7 Funding
This study was supported by unrestricted grants from the Netherlands 
Organisation of Scientific Research (ZonMw), the Ministry of Health, Welfare, 
and Sports and the Netherlands Genomics Initiative/Netherlands Organization 
for scientific research (NGI/NWO; 05040202 and 050-060-810 NCHA). 
49
HANDGRIP STRENGTH AND MORTALITY IN THE OLDEST OLD POPULATION
3
3.8 References
1.  Wetle TF. The oldest old: missed public health opportunities. Am J Public Health 2008; 98: 1159.
2.  World population ageing. 1950–2050. New York (NY): United Nations Publications; 2002. p. 23. 
Available: www .un .org/esa /population/publications/world ageing 19502050/ (accessed 
2009 Nov. 19).
3.  Bauman AE. Updating the evidence that physical activity is good for health: an epidemiological 
review 2000-2003. J Sci Med Sport 2004; 7 (Suppl 1): 6-19. 
4.  Hu FB, Stampfer MJ, Colditz GA, Ascherio A, Rexrode KM, Willett WC, Manson JE. Physical 
activity and risk of stroke in women. JAMA 2000; 283: 2961-2967.
5.  Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, Woo J, Baumgartner 
R, Pillard F, Boirie Y, Chumlea WM, Vellas B. Sarcopenia: its assessment, etiology, pathogenesis, 
consequences and future perspectives. J Nutr Health Aging 2008; 12: 433-450. 
6.  Lee JS, Auyeung TW, Kwok T, Lau EM, Leung PC, Woo J. . Associated factors and health impact of 
sarcopenia in older Chinese men and women: a cross-sectional study. Gerontology 2007; 56: 
404-410.
7.  Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55: 
M716-724.
8.  Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of 
skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci 2002; 57: 
M772-777.
9.  Giampaoli S, Ferrucci L, Cecchi F, Lo Noce C, Poce A, Dima F, Santaquilani A, Vescio MF, Menotti 
A. Hand-grip strength predicts incident disability in non-disabled older men. Age Ageing 1999; 
28: 283-288.
10.  Rantanen T, Avlund K, Suominen H, Schroll M, Frändin K, Pertti E. Muscle strength as a predictor 
of onset of ADL dependence in people aged 75 years. Aging Clin Exp Res 2002; 14 (Suppl 3): 
10-15.
11.  Alfaro-Acha A, Al Snih S, Raji MA, Kuo YF, Markides KS, Ottenbacher KJ. Handgrip strength and 
cognitive decline in older Mexican Americans. J Gerontol A Biol Sci Med Sci 2006; 61: 859-865.
12.  Metter EJ, Talbot LA, Schrager M, Conwit R. Skeletal muscle strength as a predictor of all-cause 
mortality in healthy men. J Gerontol A Biol Sci Med Sci 2002; 57: B359-365.
13.  Takata Y, Ansai T, Akifusa S, Soh I, Yoshitake Y, Kimura Y, Sonoki K, Fujisawa K, Awano S, 
Kagiyama S, Hamasaki T, Nakamichi I, Yoshida A, Takehara T. Physical fitness and 4-year 
mortality in an 80-year-old population. J Gerontol A Biol Sci Med Sci 2007; 62: 851-858.
14.  Bohannon RW. Dynamometer measurements of hand-grip strength predict multiple outcomes. 
Percept Mot Skills 2001; 93: 323-328.
15.  Innes E. Handgrip strength testing: a review of the literature. Aust Occup Ther J 1999; 46: 
120-140.
16.  Bohannon RW. Hand-grip dynamometry predicts future outcomes in aging adults. J Geriatr 
Phys Ther 2008; 31: 3-10.
17.  von Faber M, Bootsma-van der Wiel A, van Exel E, Gussekloo J, Lagaay AM, van Dongen E, Knook 
DL, van der Geest S, Westendorp RG. Successful aging in the oldest old: Who can be characterized 
as successfully aged? Arch Intern Med 2001; 161: 2694-2700.
18.  Suurmeijer TP, Doeglas DM, Moum T, Briançon S, Krol B, Sanderman R, Guillemin F, Bjelle A, van 
den Heuvel WJ. The Groningen Activity Restriction scale for measuring disability: its utility in 
international comparisons. Am J Public Health 1994; 84: 1270-1273.
19.  van Eijk L. Activity and well-being in the elderly. Groningen (the Netherlands): University of 
Groningen; 1997.
20.  Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987; 317: 1098.




22.  Martin HJ, Syddall HE, Dennison EM, Cooper C, Sayer AA. Relationship between customary 
physical activity, muscle strength and physical performance in older men and women: findings 
from the Hertfordshire Cohort Study. Age Ageing 2008; 37: 589-593.
23.  Morey MC, Sloane R, Pieper CF, Peterson MJ, Pearson MP, Ekelund CC, Crowley GM, Demark-
Wahnefried W, Snyder DC, Clipp EC, Cohen HJ. Effect of physical activity guidelines on physical 
function in older adults. J Am Geriatr Soc 2008; 56: 1873-1878.
24.  Gale CR, Martyn CN, Cooper C, Sayer AA. Grip strength, body composition, and mortality. Int J 
Epidemiol 2007; 36: 228-235.
25.  Rantanen T, Volpato S, Ferrucci L, Heikkinen E, Fried LP, Guralnik JM. Handgrip strength and 
cause-specific and total mortality in older disabled women: exploring the mechanism. J Am 
Geriatr Soc 2003; 51: 636-641.
26.  Jansen CW, Niebuhr BR, Coussirat DJ, Hawthorne D, Moreno L, Phillip M. Hand force of men and 
women over 65 years of age as measured by maximum pinch and grip force. J Aging Phys Act 
2008; 16: 24-41.
27.  Kamarul T, Ahmad TS, Loh WY. Hand grip strength in the adult Malaysian population. J Orthop 
Surg (Hong Kong) 2006; 14: 172-177.
51




Ability in instrumental activities, 
rather than gait speed, is associated 
with survival in oldest old people





Context: Assessment of physical function such as gait speed is regarded as a 
useful clinical tool to estimate survival in elderly people. However, in earlier 
reports oldest old people are underrepresented and frequently unable to perform 
functional tests. 
Objective: First, to study the association of gait speed and survival in oldest 
old people. Second, to study the association of ability in instrumental activities 
in daily living (IADL) and survival as an alternative prognostic marker of 
survival in oldest old people. 
Design, Setting, and Participants: Leiden 85-plus Study, a prospective population 
based follow-up study, including 599 participants all aged 85 years at baseline. 
Main Outcome Measure: Survival rate. 
Results: During a follow up period of 12.2 years, 542 (90.2%) participants died. 
At age 85 years, 73 participants (12.2%) were unable to perform the walking test. 
Risk for all cause mortality was elevated in participants with slowest gait speed 
(hazard ratio (HR) 2.36, 95% confidence interval (CI) 1.91-2.91, P< .001). 
Significance was lost after adjustment for common confounders (HR 1.11. 95% 
CI 0.77-157, P< .100). Poor IADL ability was associated with a higher HR 
compared to gait speed (HR, 2.75, 95% CI 2.22-3.40, P< .001), adjustment for 
all possible confounders including gait speed attenuated the relation slightly 
(HR, 1.79, 95% CI 1.27-2.52, P< .001).
Conclusions: In oldest old people aged 85 years, poor IADL ability is a better 
predictor of mortality than slow gait speed and serves as an alternative 
convenient tool for prognostication of survival among oldest old. 
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4.2 Introduction
Assessment of physical function in elderly patients is regarded as a useful tool 
in clinical practice to predict future functional outcome and survival. Population 
based longitudinal studies in elderly people have shown an association between 
poor lower extremity function and disability, hospitalization, and survival [1, 2]. 
Walking is one of the most important activities that people perform on a daily 
basis. Recently, a significant association between gait speed and survival in 
elderly people with a mean age of 73.5 years has been reported [3]. Gait speed 
is not only a parameter of muscle function, but also depends on other important 
factors such as cognition, neural control, joint function and cardiovascular 
fitness [4]. Furthermore, declining energy availability due to impaired energy 
homeostasis lowers the fatigue threshold in older people and thus contributes 
to declining physical function [5].
In geriatric medicine a considerable number of patients are over 75 years of 
age with almost 20% being older than 85 years old [6]. Demographics will 
change dramatically in the years to come and in 2050 oldest old adults will 
account for one-fifth of all older persons globally[6]. Oldest old people were 
underrepresented in earlier studies testing the relation between gait speed an 
survival and some did not adjust for factors that significantly change during 
lifetime such as cognition, depressive symptoms and physical activity [1-3].
Furthermore, inability of elderly people to perform the functional test complicates 
assessment and calls for an alternative measure of physical function, such as 
ability to perform activities of daily living. Therefore we studied the association 
of gait speed and the ability in instrumental activities of daily living (IADL) 
with survival in a comprehensive longitudinal population based cohort of 599 
oldest old people. 
4.3 Method
4.3.1 Subject characteristics
The Leiden 85-plus Study is a population-based prospective follow-up study of 
inhabitants of the city of Leiden, the Netherlands. All inhabitants who reached 
the age of 85 years were eligible to participate [8]. There were no selection 
criteria. Enrolment took place between 1997 and 1999. In total 599 persons 
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participated, 87% of all eligible inhabitants. Details are provided in a previous 
publication [9]. In short, a research nurse visited participants at their place of 
residence. During these visits interviews and performance tests were 
conducted, blood samples collected, and an electrocardiogram recorded. The 
medical history was obtained from the general practitioner or nursing home 
physician. Follow up visits were performed annually. The study was approved 
by the Medical Ethical Committee of the Leiden University Medical Center. All 
subjects gave informed consent. For persons with severe cognitive impairment, 
informed consent was given by a guardian.
4.3.2 Gait speed
Gait speed was assessed at the participant’s home using the 6 meter walking 
test. Participants were requested to walk 3 meters, turn, and walk 3 meters 
back as quickly as possible from a standing start position [10]. Gait speed was 
calculated using distance in meters and time in seconds (m/s) for 526 (87.8%) 
participants. For purpose of comparison with other studies 4 meter gait speed 
was calculated using the conversion formula used by Studenski et al [3]. Those 
participants unable to perform the 6 meter walking test were scored as 0 m/s.
4.3.3 Functional ability in instrumental activities of daily living
Ability to complete daily activities was measured at age 85 years by the 
Groningen Activity Restriction Scale (GARS) [14]. It assesses competence in 
nine instrumental abilities, that is doing light housework, heavy cleaning, 
wash and iron clothes, clean and make the bed, prepare a hot meal, climbing 
the stairs, get around outdoors, do the shopping and attend to feet and toenails. 
A summed score was calculated for basic IADL ranging from 9, (indicating 
ability) to perform all activities without assistance or undue effort), to 36 
(indicating disability). 
4.3.4 Potential confounders
The 15-item Geriatric Depression Scale (GDS-15) was used to measure depressive 
symptoms [11]. Global cognitive performance was assessed with the 
Mini-Mental State Examination (MMSE) [12]. Other variables included were 
gender, smoking history (current, past, never) and self reported health (good 
versus poor). Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared. Systolic blood pressure (SBP) was measured 
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with a mercury sphygmomanometer. Chronic diseases included cardiovascular 
disease and hypertension, diabetes mellitus, obstructive pulmonary disease, 
malignancy, Parkinson’s disease and arthritis or osteoarthrosis, which were 
identified from general practitioner and pharmacists’ records, electrocardio-
gram, and blood sample analysis [10]. Four items from the Time Spending 
Pattern questionnaire were selected to constitute physical exercise above 
routine daily physical activity [13]. They were: (a) walking for fun (b) cycling 
for fun (c) exercise alone or in groups or other physical activity and (d) working 
in the garden. Each item was scored from 0 (no activity) to 4 (daily activity) 
and their sum score made up the Physical Activity Score (PAS).
4.3.5 Follow-up
All subjects were followed up for survival until January 2010 with a follow-up 
period of 12.2 years. Dates of deaths were obtained from the Dutch civic 
registry. 
4.3.6 Statistical analysis
Gender specific tertiles for gait speed and IADL were calculated. Kaplan-Meier 
curves were applied to display survival in tertiles of baseline gait speed and 
IADL. Analysis for survival was assessed using Cox regression analyses. 
Hazard ratios (HR) for mortality were first adjusted for summed chronic 
diseases, SBP, smoking status, and self reported health (model 2). Subsequently 
models were adjusted for GDS and MMSE score (model 3), PAS score and 
walking aid use (model 4), IADL for walking speed analysis (model 5) and gait 
speed for IADL analysis (model 6). Finally the model was adjusted for all 
included factors (model 7). All analyses were repeated with 4 meter gait speed. 
Furthermore, analyses were repeated excluding participants who died within 
6 months of inclusion. All statistical analyses were performed using SPSS for 




After a follow up period of 12.2 years 542 (90.2%) participants died. At the age 
of 85 years, mean (SD) gait speed was 0.46 (0.3) m/s for the entire study population 
and 0.52 (0.2) m/s for the participants who were able to perform the walking 
test. Seventy-three (12.2%) participants did not perform the walking test due 
to physical limitations (n=62, 10.4%), severe cognitive impairment (n=5, 
0.8%), refusal (n=3, 0.5%) or technical difficulties (n=3, 0.5%). The characte-
ristics of the participants being able to perform the walking test and the 
ones who did not perform the test are given in table 1. The participants who 
did not perform the test were more likely to live institutionalized, were more 
dependent in ADL and had worse cognitive function. 
Figures 1A and 1B show the Kaplan-Meier cumulative survival curves for 
all-cause mortality according to gender specific tertiles of gait speed for the 
entire study population and ability to perform the 6 meter walking test, 
respectively. Table 2 presents the HR for all-cause mortality stratified by 
tertiles of gait speed at age 85 years (left panel). The tertile of the fastest gait 
speed was used as the reference group (women > 0.55 m/s and men > 0.67 
m/s). Slow gait speed (women < 0.32 m/s and men < 0.43 m/s) was associated 
with the highest HR for mortality (HR, 2.36; 95% CI 1.91-2.91, P< .001, model 1). 
Further adjustment for chronic diseases, BMI, smoking, systolic blood pressure 
and self reported health (model 2) attenuated results slightly, as did additional 
adjustment for GDS and MMSE in model 3 and PAS and walking aid use (model 
4). Moderate gait speed was significantly associated with mortality (HR 1.41, 
95% CI 1.14-1.74, P= 001, model 1). The significant association between slowest 
and moderate gait speed with mortality was lost after adjustments for IADL 
(model 5) and in the fully adjusted model 7 (both, P> .080). Repeating the 
analysis for the 526 participants who were able to perform the walking test did 
not change the results. Inability to perform the 6 meter walking test was 
associated with a high mortality risk (HR 2.70, 95% CI 2.10-3.48, P< .001). 
Due to the inability of 12.2% of oldest old people to perform the walking test, 
we studied the association between IADL questionnaire scores and mortality. 
Figure 1C shows the Kaplan-Meier cumulative survival curve for all-cause 
mortality stratified for gender specific IADL tertiles. As shown in table 2 (right 
panel), poor IADL ability was associated with a higher HR for mortality compared 
to gait speed (HR 2.75, 95% CI 2.22-3.40, P< .001, model 1). In the fully adjusted 
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model (including gait speed), poor IADL ability was still significantly associated 
with a higher mortality risk (HR, 1.79, 95% CI 1.27-2.52, P< .001). Moderate 
IADL ability was not associated with increased mortality. Exclusion of participants 
who died within 6 months after inclusion and using the calculated 4 meter gait 
speed did not change results for gait speed and IADL (data not shown). 
Table 1   Characteristics of participants at 85 years stratified by ability to 
perform the walking test






Men (number, %) 203 (33.9) 189 (35.9) 14 (19.2)
Widowed (number, %) 345 (57.6) 291 (55.3) 54 (74.0)
Living arrangements
Independent (number, %) 329 (54.9) 314 (59.7) 14 (20.6)
Sheltered (number, %) 160 (26.7) 152 (28.9) 8 (11.0)
Institutionalized (number, %) 110 (18.4) 60 (11.4) 50 (68.5)
Health characteristics
Body Mass Index (mean, SD) 27.2 (4.5) 27.2 (4.5) 27.2 (4.7)
Good self reported health (number, %) 418 (69.8) 379 (72.1) 37 (61.7)
Geriatric Depression Scale (points, median, IQR) 2 (1-3) 2 (1-3) 3 (2-5)
Mini Mental State Examination  
(points, median, IQR)
26 (22-28) 26.5 (24-28) 18 (4-23)
Comorbidity* (number, median, IQR) 2 (1-3) 2 (1-3) 2 (1-3)
Functional ability
Personal activities of daily living  
(points, median, IQR)†
10 (9-15) 9 (9-12) 27 (17-33)
Instrumental activities of daily living  
(points, median, IQR)†
18 (12-27) 16 (12-24) 35 (33-36)
Physical Activity Score (points, median, IQR)§ 7 (4-8) 7 (5-9) 4 (4-6)
Gait speed (m/s, mean, SD) 0.46 (0.3) 0.52 (0.2) n.a.
No walking aid  
(cane, walker, support of other person)
438 (73.4) 436 (82.9) 2 (2.7)
Abbreviations: IQR, interquartile range; n.a, not applicable. 
 *Comorbidity is summed score of chronic diseases including cardiovascular disease, hypertension, 
diabetes mellitus, obstructive pulmonary disease, malignancy, Parkinson’s disease and arthritis 
or osteoarthrosis; † Groningen activity restriction scale (GARS) total score can range from 9 (not 
disabled) to 36 points (severely disabled); § physical exercise above routine daily physical activity: 
(a) walking for fun, (b) cycling for fun, (c) exercise alone or in groups or other physical activity, and 




Figure 1   Kaplan-Meier cumulative survival curves for all-cause mortality 
according to (A) gender specific tertiles of gait speed, including 
oldest old people who were not able to perform the walking test,  
(B) ability to perform walking test and (C) gender specific tertiles of 
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4.5 Discussion 
Gait speed was associated with survival in a cohort of oldest old people aged 85 
years of the general population with a follow up of 12.2 years. However, the 
predictive value of gait speed was significantly weakened after adjustment for 
cognition, depressive symptoms, IADL, and life style. Inability to perform a walking 
test was highly discriminative of poor survival. Furthermore, IADL disability was 
associated with a higher predictive value for poor survival in oldest old people 
compared to gait speed, independent of common confounders and gait speed. 
In contrast to earlier findings in approximately 10 years younger older adults 
[1-3], lower gait speed was not predictive for poor survival in oldest old 
people after adjustment for common confounders and may not refine survival 
estimates in clinical practice in this age group. Assessment of IADL ability by 
use of questionnaire might be a better predictor of survival compared to gait 
speed and earlier reported functional tests such as handgrip strength [15].
The strengths of this study are related to its design. The Leiden 85-plus Study 
is a longitudinal population based cohort study with extensive measures for 
health and functioning with a follow up of 12 years. Therefore the results can 
be generalized to the western population of oldest old. Possible limitations are 
that gait speed was not measured at usual speed from a standing position, but 
participants were instructed to walk as fast as possible, this might have 
underestimated the predictive value of gait speed because frail elderly could 
not complete the test. However, as others we have included the participants 
unable to perform the walking test into the analysis [16]. Also the association 
between IADL and survival was tested in a cohort of the general population 
and not in a clinical population of oldest old people, but it is likely that the 
association between IADL ability and survival will be even stronger. 
Our findings showed that in oldest old people slow gait speed was associated 
with an increased risk of poor survival compared to fastest gait speed. 
However, adjustment for common confounders weakened the association 
considerably. Including only able participants into the analysis did not change 
the results. Furthermore, in clinical practice we expect a larger proportion of 
oldest old patients to be unable to perform a walking test due to functional 
limitation and cognitive impairment. In case of inability to walk, assessment of 
IADL disability by questionnaire, which is already part of the comprehensive 
geriatric assessment, could be a good alternative to predict survival. 
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These findings contribute to the body of knowledge about the growing segment 
of the oldest old people and cautions us not to generalize findings in old people 
to oldest old people. It also emphasizes the need for further studies to find 
suitable clinical prognostic markers for survival in oldest old people. 
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depressive symptoms, independent of 
cognitive function and comorbidity. 
A prospective population based study 
among oldest old people
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Objective: To assess the longitudinal association of depressive symptoms with 
functional ability in oldest old people.
Methods: population based cohort study over a period of five years, including 
500 people, all aged 85 years at baseline. Depressive symptoms by Geriatric 
Depression Scale (GDS-15). Ability in personal (ADL) and instrumental activities 
of daily living (IADL) by self report. Associations between GDS-15 and functional 
ability were analyzed by linear regression adjusted for comorbidity and cognitive 
function.
Results: Higher GDS-15 score was associated with increased ADL and IADL 
disability at 85 and 90 years (all, P< 0.001). In the longitudinal analysis, change 
in GDS-15 score between age 85 and 90 years was associated with change in 
ADL (0.51 points per 1 point change in GDS-15 score, P< 0.001) and IADL ability 
(0.66 points per 1 point change in GDS-15 score, P< 0.001). However, baseline 
GDS-15 score was not associated with increased ADL and IADL disability, but 
better baseline IADL ability was associated with a smaller increase in GDS-15 
score (-0.10 point per 1 point IADL, P= 0.020). Furthermore, steeper decline in 
ADL and IADL ability was associated with a higher GDS-15 score at age 90 
years (+0.18 point per 1 point ADL, +0.14 point per 1 point IADL, all P< 0.001). 
Conclusion: Functional ability has a strong association with future depressive 
symptoms, independent of cognitive function and comorbidity. Further work 
should occur to determine whether rehabilitation therapy is associated with 
improvement in depressive symptoms.
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5.2 Introduction
Depression and depressive symptoms are common in oldest old people with 
prevalences ranging between 13-48% in persons aged over 80 years. Prevalence 
is variable and depends on country, criteria used for depression, age, place of 
residence, and cognitive impairment amongst other factors [1]. Despite the high 
prevalence of depression and depressive symptoms and associated adverse 
outcomes it is poorly recognized and undertreated in oldest old people [1, 2].
Depressive symptoms have been demonstrated to be associated with cognitive 
impairment, comorbidity, functional disability and mortality [1, 3- 5]. However, 
most of the studies concerning depression and depressive symptoms in older 
people have been carried out in younger old subjects. Recent reviews regarding 
this topic have shown that the number of longitudinal studies in people older 
than 85 years is limited [1-5].
By 2050, the oldest old will account for one-fifth of all older persons globally 
[6]. It is therefore important to study the longitudinal associations of depression 
and depressive symptoms with cognition, chronic diseases and functional 
ability in oldest old people. This study examines the cross-sectional and 
longitudinal association of depressive symptoms with functional ability in the 
oldest old and aims to determine whether this association is independent of 
cognitive ability and comorbidity.
5.3 Methods
The Leiden 85-plus Study is a cohort study of all people aged 85 years who 
lived in the city of Leiden, The Netherlands. Recruitment to the study took 
place between 1997 and 1999 and all city residents (including people living in 
nursing homes) who reached the age of 85 years were eligible to participate 
and there were no selection criteria related to health or demographic factors 
[7]. A total of 599 persons participated in the study, 87% of all who were 
eligible. Data were collected by a research nurse who visited participants at 
their place of residence. The medical history was obtained from the medical 
practitioner providing primary medical care.
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The study was approved by the relevant health research ethics committee. 
Participants gave informed consent. Where severe cognitive impairment was 
present consent was given by the person legally permitted to do this. 
5.3.1 Depressive symptoms and cognitive function
The validated Dutch 15-item Geriatric Depression Scale (GDS-15) was used to 
measure depressive symptoms [8, 9]. Because of limited validity of the GDS-15 
in people with moderate and severe cognitive impairment it was completed 
only by people with MMSE scores below 19 points (N= 500) [10, 11]. Cognitive 
functioning was measured using the Mini Mental Status Examination (MMSE) [12].
5.3.2 Functional ability in activities of daily living
Ability to complete daily activities was measured by the Groningen Activity 
Restriction Scale (GARS) [13]. It assesses competence in abilities in nine 
personal basic activities of daily living (ADL) and nine instrumental activities 
of daily living (IADL). In case of an MMSE score below 19 points, information 
on competence and actual performance in daily activities was obtained from a 
guardian. A summed score was calculated for basic ADL ranging from 9, 
(indicating reported ability to perform all activities without assistance or 
undue effort), to 36 (indicating inability to perform any activity without help). 
A similar score was calculated for IADL with the same range. Ability in 
activities of daily living was assessed at age 85 and 90 years.
5.3.3 Potential confounders
Gender, income (dichotomized around the median net (after-tax) monthly 
income per household), education (higher and lower education level, with the 
latter defined as no schooling or a maximum of six years of primary schooling) 
were listed. Chronic diseases included cardiovascular disease and hyper -
tension, diabetes mellitus, obstructive pulmonary disease, malignancy, 
Parkinson’s disease and arthritis or osteoarthrosis, which were identified 
from general practitioner and pharmacists’ records, ECG and blood sample 
analysis. For details on classification of chronic diseases we refer to a previous 
publication [14]. Comorbidity was defined as the sum of all included chronic 
diseases. No adjustments were made in the analysis for use of antidepressant 
drug therapy, due to the fact that only 9 (1.5%) participants used antidepressant 
drugs [2].
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5.3.4 Statistical analysis 
The cross-sectional association between ADL and IADL at age 85 and 89 years 
was tested in gender specific tertiles of baseline GDS-15 score by linear 
regression. 
In order to assess the relationship over time between changes in GDS-15 score 
and functional ability we first analyzed if changes in GDS-15 scores between 
age 85 and 90 years were significantly associated with changes in ability in 
activities of daily living during follow up. Second, we analyzed the longitudinal 
association between GDS-15 scores at 85 years and changes in functional 
ability between age 85 and 90 years. Then, the association between functional 
ability at age 85 years and change in GDS-15 score between age 85 and 90 years 
was analyzed. Finally, we analyzed if a change in activities of daily living 
between age 85 and 90 years predicted GDS-15 score at 90 years. 
All analyses were adjusted first for gender, and then additionally for income 
and education. Subsequently models were adjusted for either comorbidity or 
MMSE. Finally the model was adjusted for all of these five factors. We took this 
approach as each of these factors may influence the association of interest.
5.4 Results
5.4.1 Baseline characteristics 
Table 1 provides characteristics of the 500 participants at baseline. Depressive 
symptoms (GDS-15 score≥ 4 points) were present in 119 (23.8%) of the 
participants at age 85 years. Twenty-nine (5.8%) had a GDS-15 score≥ 8 points. 
GDS-15 score was not available in ninety-nine (16.5%) participants with an 
MMSE score below 19 points. Excluded participants were more likely to be 
female, had lower education, and lower income (all, p< 0.001). At age 90 years, 
246 (50.8 %) participants were alive. Within this group GDS-15 scores were 
available in 202 (40.4%) participants of the entire baseline population. 
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5.4.2  Cross sectional associations between depressive symptoms 
and functional ability
Figure 1 shows the cross-sectional association between personal and instrumental 
activities of daily living tertiles of GDS-15 score at age 85 and 89 years. The 
highest tertile of GDS-15 score was significantly associated with increased 
ADL and IADL disability (P< 0.001) in the fully adjusted model. At age 85 years 
ADL disability increased by 0.62 points per 1 point increase in GDS-15 score 
(P< 0.001) and IADL disability increased by 1.21 points per 1 point increase in 
GDS-15 score (P< 0.001). At age 90 years, increase in ADL and IADL disability 
per 1 point increase in GDS-15 score was 0.57 and 0.95 points respectively 
(P< 0.001). The significant association remained after adjustment for multiple 
possible confounders (all, P< 0.001). The strength of the association was 
greater for IADL than ADL. Repeating the analysis with all individual chronic 
diseases instead of the summed score of comorbidities did not change these 
results. Therefore only the results for comorbidity as a measure of chronic 
diseases are presented. 
Table 1   Characteristics of participants at baseline (85 years)
N= 500
Men (N, %) 184 (36.8) 
Widowed (N, %) 277 (55.4) 
Living arrangements
Independent (N, %) 295 (59.0) 
Sheltered (N, %) 148 (29.6) 
Institutionalized (N, %) 57 (11.4) 
General health and functional ability
Depressive symptoms* (N, %) 119 (23.8) 
Cognitive impairment† (N, %) 85 (17.0) 
≥ 3 chronic diseases‡ (N, %) 171 (39.6)
Personal activities of daily living (points, IQR)§ 9 (9-12)
Instrumental activities of daily living (points, IQR)§ 16 (12-23)
* GDS-15 = Geriatric Depression Scale 15 items, score ≥ 4 points; † Mini Mental State Examination 
score < 19 points; ‡ Chronic diseases included cardiovascular disease and hypertension, diabetes 
mellitus, obstructive pulmonary disease, malignancy, Parkinson’s disease and arthritis or osteo-
arthrosis ; § Functional ability: total score can range from 9-36 points (best to worst) , IQR inter-
quartile range.
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5.4.3  Longitudinal associations between depressive symptoms and 
functional ability 
Change in GDS-15 score between ages 85 and 90 years was significantly associated 
with changes in functional ability in the same time period (all, P< 0.001). Change 
in GDS score by 1 point was associated with concomitant change in ADL and IADL 
score with 0.49 and 0.68 points respectively (all, P< 0.001). Results remained 
similar after adjustment for multiple possible confounders. Table 2 presents the 
association between GDS-15 score at 85 years and changes in functional ability 
between age 85 and 90 years. GDS-15 score at age 85 years was not associated 
with changes in functioning in activities of daily living over the following 5 years. 
Table 3 presents the association between ability in activities of daily living at age 
85 years and change in GDS-15 score between age 85 and 90 years. Better baseline 
ability in IADL was associated with a smaller change in GDS-15 score after 
adjusting for multiple possible confounders (-0.10 points per 1 point IADL, P= 
0.020). No association was found for baseline personal activities of daily living (all, 
P> 0.200). The association between increasing disability in activities of daily 
living between age 85 and 90 years and GDS-15 score at 90 years is presented in 
table 4. A steeper decline in both ADL and IADL was associated with a significantly 
higher GDS-15 score at follow-up after adjusting for baseline GDS-15 score. In the 
fully adjusted model GDS-15 score increased with 0.18 points per 1 point decline 
in ADL (P< 0.001) and 0.14 points per 1 point decline in IADL (P= 0.001). 
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Table 2   Association between GDS-15 score at age 85 years and change in 
functional ability 
 Change in ADL 
(n= 202)
Change in IADL 
(n= 202)
Points (SE) P value Points (SE) P value
GDS-15 (points) 
Model 1: Adj. for sex, functional ability  
at 85 years
-0.34 (0.20) 0.088 -0.28 (0.20) 0.155
Model 2: as 1 and income, education -0.31 (0.21) 0.133 -0.27 (0.20) 0.182
Model 3: as 2 and comorbidity -0.29 (0.21) 0.164 -0.26 (0.20) 0.197
Model 4: as 2 and MMSE at age 85 -0.18 (0.21) 0.386 -0.19 (0.20) 0.357
Model 5: adj. for all variables -0.15 (0.21) 0.460 -0.18 (0.20) 0.381
 
Note: GDS-15= Geriatric Depression Scale 15 items; ADL= personal activities of daily living; IADL= 
instrumental activities of daily living; MMSE= Mini Mental State Examination score. SE= standard 
error. Comorbidity is the sum of all included chronic diseases: cardiovascular diseases and 
hypertension, diabetes mellitus, chronic obstructive pulmonary disease, malignancy, Parkinson’s 
disease and arthritis and or osteoarthrosis. Functional ability: total score can range from 9-36 
points (best to worst).
Table 3   Association between functional ability at age 85 years and change in 
GDS-15 score (n= 202)
Change in GDS-15 
Points (SE) P value
ADL (points)
Model 1: Adj. for sex, GDS-15 at 85 years -0.06 (0.08) 0.504
Model 2: as 1 and income, education -0.10 (0.09) 0.287
Model 3: as 2 and comorbidity -0.12 (0.09) 0.197
Model 4: as 2 and MMSE at 85 years -0.10 (0.10) 0.298
Model 5: adj. for all variables -0.12 (0.10) 0.204
IADL (points)
Model 1: Adj. for sex, GDS-15 at 85 years -0.07 (0.04) 0.077
Model 2: as 1 and income, education -0.08 (0.04) 0.048
Model 3: as 2 and comorbidity -0.10 (0.04) 0.019
Model 4: as 2 and MMSE at 85 years -0.08 (0.04) 0.050
Model 5: adj. for all variables -0.10 (0.04) 0.020
Note: GDS-15= Geriatric Depression Scale 15 items; ADL= personal activities of daily living; IADL= 
instrumental activities of daily living; MMSE= Mini Mental State Examination score. SE= standard 
error.  Comorbidity is the sum of all included chronic diseases : cardiovascular diseases and 
hypertension, diabetes mellitus, chronic obstructive pulmonary disease, malignancy, Parkinson’s 
disease and arthritis and or osteoarthrosis. Functional ability: total score can range from 9-36 
points (best to worst).
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5.5 Interpretation 
This study suggests that current functional ability in personal and instrumental 
activities of daily living are primarily associated with depressive symptoms in 
oldest old people. Over time current level of instrumental disability was 
associated with an increase in depressive symptoms. Moreover, increasing 
personal and instrumental disability was associated with increasing depressive 
symptoms after 5 years follow up. This association was independent of cognitive 
functioning for people with mild dementia or normal cognitive functioning, 
and comorbid chronic diseases. Furthermore, depressive symptoms at baseline 
were not associated with increased functional disability in oldest old people. 
Table 4   Association between decline in functional ability and GDS-15 score at 
age 90 years
GDS at age 90 years 
(n= 202)
Points (SE) P value
Decline in ADL (85-90 years, points)
Model 1: Adj. for sex, GDS-15 score at 85 years 0.18 (0.04) ≤ 0.001
Model 2: as 1 and income, education 0.18 (0.04) ≤ 0.001
Model 3: as 2 and comorbidity 0.18 (0.04) ≤ 0.001
Model 4: as 2 and MMSE at 85 years 0.18 (0.04) ≤ 0.001
Model 5: adj. for all variables 0.18 (0.04) ≤ 0.001
Decline in IADL (85-90 years, points)
Model 1: Adj. for sex,  GDS-15 score at 85 years 0.14 (0.03) ≤ 0.001
Model 2: as 1 and income, education 0.14 (0.03) ≤ 0.001
Model 3: as 2 and comorbidity 0.14 (0.03) 0.001
Model 4: as 2 and MMSE age at 85 years 0.14 (0.03) ≤ 0.001
Model 5: adj. for all variables 0.14 (0.03) 0.001
Note: GDS-15= Geriatric Depression Scale 15 items; ADL= personal activities of daily living; IADL= 
instrumental activities of daily living; MMSE= Mini Mental State Examination score. SE= standard 
error.  Comorbidity is the sum of all included chronic diseases : cardiovascular diseases and 
hypertension, diabetes mellitus, chronic obstructive pulmonary disease, malignancy, Parkinson’s 
disease and arthritis and or osteoarthrosis. Functional ability: total score can range from 9-36 
points (best to worst).
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This is a very important finding in understanding risk factors for depressive 
symptoms in very old people. It suggests that greater emphasis should be 
placed on the recognition of personal and instrumental functional disability 
and whether they are increasing as the person ages.
Whether it is possible to positively change depressive symptoms in oldest old 
people is not clear. It has previously been shown in an undertreated oldest old 
population that depressive symptoms did not commonly remit [15]. However, 
our study is an observational study and further intervention studies are 
needed to evaluate if improvement of functional ability or strategies to 
compensate for disability are successful in prevention of depressive symptoms. 
A recent review identified only 20 longitudinal studies on the association 
between depression, depressive symptoms, and functional ability in elderly 
people aged over 60 years [5]. Depression was associated with functional 
decline, and conclusions regarding the contribution of cognitive decline or 
comorbidity were inconclusive. A recent longitudinal study with a 3 year follow 
up found that depression was associated with higher risk of poor functional 
outcome in 481 participants with a mean age of 75 years [16]. We found depressive 
symptoms to be associated with functional disability in the cross-sectional 
analysis, but surprisingly could not establish a longitudinal relationship between 
current depressive symptoms and functional decline over time in oldest old 
people. We conclude that functional ability preceeds depressive symptoms 
after 5 years follow up. Functional decline over time was also found to be 
associated with an increased risk of depressive symptoms (measured by GDS-15) 
at follow-up in a population of elderly patients with chronic obstructive pulmonary 
disease [17].
The strengths of this study are related to its design as a population based 
cohort. As a result it is highly representative of very old people living in a 
developed western county. However, it should be noted that people with 
moderate to severe impairment of cognitive functioning (MMSE < 19 points) 
were not included in the analyses and therefore the findings are not 
generalisable to that group. This is about 20% of the population at age 85 
years. Another limitation of our study is that depressive illness was not 
formally diagnosed. The GDS–15 was originally developed as a screening 
instrument for depressive illness in older adults but it has been extensively 
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used in epidemiological studies involving older people [5, 15, 18]. There is a 
long period between the baseline measurement and follow up and one could 
argue that intercurrent events that cause transient functional disability have 
not been captured adequately. However, earlier it has been shown that only in 
a minority of older people patterns of disability were characterized by an 
episode of recovery [19]. Finally, in the study cohort there was substantial 
attrition due to death and cognitive decline. However, this will inevitably 
affect all studies of very old people and should not necessarily be seen as a 
weakness. 
Stek and colleagues concluded that depression was frequent and highly 
persistent in this oldest old cohort.15 We add that current IADL disability and 
steeper decline in functional ability have a strong association with future 
depressive symptoms and consequently on the requirement for support services 
from family members and external providers. There is a substantial cost, both 
material and psychological, as a result. Functional ability should be carefully 
assessed in oldest old people because of its strong associations with depressive 
symptoms in future, independent of cognitive decline and comorbidity. These 
are strong reasons to detect and intervene with older people with declining 
functional ability as a possible means to prevent depressive symptoms during 
ageing. Further work should occur to determine whether rehabilitation therapy 
is associated with improvement in depressive symptoms.
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Background: Cognitive decline and muscle weakness are prevalent health 
conditions in elderly and often co-occur. We hypothesized that cognitive decline 
precedes muscle weakness. The aim of this study was to analyze the temporal 
relationship between cognitive performance and handgrip strength in oldest 
old people.
Method: Leiden 85-plus Study, a prospective population based four year 
follow-up study of 555 subjects, all aged 85 years at baseline. A neuropsycho-
logical test battery was used to assess global cognitive performance attention, 
processing speed and memory. Subjects were followed up over a four year 
period with repeated cognitive tests. Handgrip strength was measured at age 
85 and 89 years as a proxy for muscle strength. Cross-sectional and prospective 
associations between cognitive performance and handgrip strength were 
analyzed by linear regression analysis adjusted for anthropometry, income, 
education, comorbidity, and physical activity.
Results: At age 85 and 89 years, better cognitive performance was associated 
with higher handgrip strength (all, P< .03), except for attention. In the longitudinal 
analysis, better cognitive performance at age 85 years was associated with 
slower decline in handgrip strength in the following four years after adjustment 
for possible confounders (all, P< .01). There was no longitudinal association 
between baseline handgrip strength and cognitive decline (all, P> .10), except 
for global cognitive performance (P= .007). 
Conclusions: Baseline cognitive performance was associated with change in 
handgrip strength, whereas baseline handgrip strength was not associated 
with cognitive decline. Our results suggest that cognitive decline precedes the 
onset of muscle weakness and not vice versa.
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6.2 Introduction
Cognitive decline and muscle weakness are highly prevalent health conditions 
in elderly and often co-occur in elderly persons. Both conditions predict 
detrimental outcome in elderly, such as functional impairment and mortality 
[1-5]. Symptoms related to cognitive decline are amongst others, functional 
impairment, muscle weakness and sarcopenia [6-15]. Handgrip strength and 
walking speed have been associated with cognitive decline in cross-sectional 
studies [6, 7, 11-13]. Furthermore, handgrip strength has been associated with 
an accelerated decline in global cognitive performance [5, 8] and higher risk of 
Alzheimer’s disease and Mild Cognitive Impairment in longitudinal studies 
[10, 14]. Therefore, handgrip strength is a potential early marker of cognitive 
decline and incident dementia. Based on these findings it has been proposed to 
screen older people for signs of functional impairment to identify those elderly 
at risk of developing cognitive decline in future [5, 10]. 
The temporal relationship between decline of muscle strength and cognitive 
performance is still unclear. Does poor handgrip strength precede and therefore 
mark cognitive decline or is the opposite the case. Longitudinal studies on this 
topic focused on the relationship between muscle strength and subsequent 
cognitive decline [5, 8, 10, 14, 15]. So far, only one other study reported on the 
relationship between cognitive and functional decline and concluded that 
cognitive decline preceded functional decline in elderly women [16].
We hypothesized that cognitive decline precedes muscle weakness based on 
the knowledge that motor skill learning and motor output depend on activity 
of frontal and parietal brain regions [17-20]. Also, there is evidence for an 
interaction and interconnection of the cognitive and motor brain regions with 
regard to motor output [20]. 
The aim of the present study was to analyze the temporal relationship between 
cognitive performance and handgrip strength in a prospective population 





The Leiden 85-plus Study is a population-based prospective follow-up study of 
inhabitants of the city of Leiden, the Netherlands. All inhabitants who reached 
the age of 85 years were eligible to participate. There were no selection criteria 
on health, functioning or demographic characteristics. Enrolment took place 
between 1997 and 1999. In total 599 persons participated, 87% of all eligible 
inhabitants. Details are provided in a previous publication [21]. In short, a 
research nurse visited subjects at their place of residence. During these visits 
interviews and performance tests were conducted, blood samples collected, 
and an electrocardiogram recorded. The medical history of all subjects was 
obtained from the general practitioner or treating nursing home physician. 
Follow up visits were annually performed.
The study was approved by the Medical Ethical Committee of the Leiden University 
Medical Center. All subjects gave informed consent. For persons with severe 
cognitive impairment, informed consent was given by a guardian.
6.3.2 Cognitive performance
Global cognitive performance was assessed with the Mini-Mental State 
Examination (MMSE). In addition, a dedicated neuropsychological test battery 
was used to assess specific cognitive performance in all subjects with an 
MMSE score ≥ 19 points for reasons of test validity. Attention and processing 
speed were assessed by use of the abbreviated Stroop test trial 3 and the Letter 
Digit Substitution Task (LDST). Memory function was assessed with the 
12-Picture Learning Test (12-PLT, immediate and delayed recall). 
The MMSE is a widely used test developed as a screening instrument for dementia. 
It provides a reliable measure of global cognitive performance and ranges from 0 
to 30 points, with lower scores indicating worse cognitive performance [22]. The 
abbreviated Stroop test is a measure of attention, consisting of 3 trials in which 
the subject has to name 40 items shown on a card [23, 24]. In trial one, the card 
contains color-names printed in black and subjects are asked to name the printed 
word. In trial two, the card contains colored blocks and subjects are asked to name 
the printed color. In trial three, the card contains color-names printed in a different 
color than the color-name and subjects are asked to name the color of the ink. The 
outcome variable is the time needed to finish trial 3 with higher scores indicating 
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worse performance. The LDST is a modified version of the Symbol Digit Modalities 
Test, measuring processing speed [25]. Subjects make as many letter-digit 
combinations as possible within 60 seconds, following an example that shows the 
correct combinations, with higher scores indicating better performance. Memory 
function was assessed with the 12-PLT, a measure of memory function with 
immediate recall and delayed recall components [26]. In the immediate recall part 
of the test, subjects are shown pictures of 12 different objects and then asked to 
recall as many as possible. This is done three consecutive times with the total 
number of correct answers after the third time as the outcome variable. After 20 
minutes subjects are asked again to recall the 12 objects. This number is the 
outcome variable for the delayed recall. For both parts of the test higher scores 
indicate better performance.
MMSE was measured yearly until end of follow up. The neuropsychological 
test battery was assessed yearly until end of follow up or until MMSE score 
was below 19 points. For the present study cognitive performance scores at 
age 85 and 89 years were included in the analysis. 
6.3.3 Handgrip strength
Handgrip strength is a surrogate measurement of overall muscular strength 
[27-29]. Handgrip strength was measured using a Jamar hand dynamometer 
(Sammons Preston Inc, Bolingbrook, IL) to the nearest kilogram (Kg). All 
subjects were instructed to maintain an upright standing position, arms down 
by the side, and holding the dynamometer in the dominant hand without 
squeezing the arm against the body. The width of the dynamometer’s handle 
was adjusted to the hand size of the subjects such that the middle phalanx 
rested on the inner handle. Subjects were allowed to perform one test trial, 
followed by three trials and the highest value was taken for analysis. Handgrip 
strength was measured at two time points, at age 85 and 89 years. 
6.3.4 Potential confounders
Anthropometric data were collected for all subjects. Net (after-tax) monthly 
income per household was obtained during face-to-face interviews asking 
standardized questions about state pension, other pensions and additional 
income per month, followed by an open question about the net amount for each 
category. Income was dichotomized around the median. Education was rated 
into two levels: a lower education level, including subjects without schooling, 
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or with primary school education only (with a maximum of six years of 
schooling), and those with a higher education level (equivalent to more than 
six years of schooling). Severity of diseases was estimated by the number of 
prescription medication. Baseline data on chronic somatic diseases were 
available from the general practitioner, pharmacist’s records, electrocardio-
gram, and blood sample analysis. Chronic diseases included myocardial infarction, 
stroke, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, 
malignancy, rheumatoid arthritis and osteoarthrosis [21]. Comorbidity was 
defined as a sum score of all chronic diseases per subject. 
Physical activity was assessed by the Time Spending Pattern questionnaire 
[30]. Four items from this questionnaire were selected to constitute physical 
exercise above routine daily physical activity: (a) walking for fun, (b) cycling 
for fun, (c) exercise alone or in groups or other physical activity, and (d) 
working in the garden. Each item was scored from 0 (no activity) to 4 (daily 
participating in activity) and their sum score made up the Physical Activity 
Score which was used as indicator for physical activity levels. Depressive 
symptoms were assessed by the 15-item Geriatric Depression Scale (GDS) [31]. 
6.3.5 Statistical analysis
All cross-sectional and longitudinal associations between cognitive performance 
and handgrip strength were analyzed by linear regression using three 
different models. In model 1, the analysis was adjusted for gender, height, and 
weight. Model 2 was adjusted as model 1 with further adjustments for income, 
education, number of medication and GDS. Model 3 was adjusted as model 2 
with further adjustment for physical activity score. In the longitudinal analysis 
the outcome variable was either the decline in handgrip strength or cognitive 
performance (from age 85 to 89 years), further adjustments were made in 
model 1 for baseline cognitive performance and handgrip strength respectively. 
The use of comorbidity instead of number of prescription medication did not 
alter the results of models 2 and 3, therefore only the results for the number of 
prescription medication, estimating severity of diseases, are presented in this 
paper. To visualize the relation between handgrip strength and cognitive 
performance, handgrip strength was plotted against tertiles of cognitive test 
scores. SPSS 17.0 for Windows was used for all analyses. P values <.05 were 
considered statistically significant. 
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At baseline, handgrip strength was measured in 555 subjects (92.7 %) of 599 
subjects of the Leiden 85-plus Study. Figure 1 shows the flow chart of subjects 
between age 85 and 89 years. The baseline characteristics of the study population 
are shown in table 1. 
6.4.2  Cross sectional association between cognitive performance 
and handgrip strength
Figure 2 shows the mean handgrip strength according to tertiles of cognitive 
test scores at (A) age 85 years and (B) at 89 years. Table 2 presents the cross-
sectional linear regression analyses of the association between cognitive 
performance and handgrip strength at age 85 years and 89 years. Higher mean 
cognitive test scores were significantly associated with higher mean handgrip 
strength after adjustment for sex, height, and weight (P< .001), except for the 
Stroop test. Adjustment for socioeconomic status, number of prescription 
medication and depressive symptoms weakened the relationship (model 2). 
Figure 1   Flow of subjects between age 85 and 89 years
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At age 85 years significance for most of the cognitive performance tests 
and handgrip strength was attenuated after further adjustment for physical 
activity (model 3). At age 89 years the positive relationship between cognitive 
performance and handgrip strength remained significant after full adjustment 
(model 3). 
6.4.3  Longitudinal association between baseline cognitive performance 
and decline in handgrip strength
Figure 2C shows the mean decline in handgrip strength from age 85 to 89 
years in tertiles of cognitive performance. Table 3 presents the results of the 
Table 1   Characteristics of subjects aged 85 years at baseline
n = 555
Men, N (%) 194 (35.0)
Widowed, N (%) 314 (56.6)
Living arrangements 
  Independent, N (%) 319 (57.5)
  Sheltered, N (%) 156 (28.1)
  Institutionalized, N (%) 80 (14.4)
Health characteristics
Mean handgrip strength, mean (SD), Kg
Men 30.6 (8.2)
Women 18.7 (5.5)
≥ 3 chronic diseases*, N (%) 186 (33.5)
Depressive symptoms† , median (IQR), points 2 (1-3)
Physical Activity Score, mean (SD), points 7.2 (2.4)
Prescription medication, median (IQR), No. 3 (1-5)
Cognitive performance
MMSE‡, median (IQR), points 26 (23-28)
Stroop test§, trial 3, median (IQR), seconds 75.1 (59.6-97.6)
LDST¶, mean (SD), correct answers 17.1 (7.1)
12-PLT#, immediate recall, mean (SD), pictures 24.0 (5.8)
12-PLT#, delayed recall, mean (SD), pictures 8.7 (2.7)
Abbreviations: N, number; Kg, kilogram; SD, standard deviation; IQR, interquartile range MMSE, 
Mini Mental State Examination; LDST, Letter Digit Substitution Task; 12-PLT, 12-Picture Learning 
Test. * Chronic diseases included myocardial infarction, stroke, hypertension, diabetes mellitus, 
chronic obstructive pulmonary disease, malignancy, rheumatoid arthritis and osteoarthrosis; †GDS-
15 = Geriatric Depression Scale 15 items, score ≥ 4 points. GDS was restricted to subjects with MMSE 
> 18; ‡n = 555; §n = 444; ¶n = 437; #n = 458.
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Figure 2   Handgrip strength in tertiles of cognitive test scores at (A) age 85 
years and at (B) age 89 years and (C) decline in handgrip strength 
between age 85 and 89 years in tertiles of cognitive performance
Mean handgrip strength at (A) age 85 and (B) 89 years in tertiles of baseline cognitive performance 
and (C) decline in handgrip strength from age 85 to 89 years in tertiles of baseline cognitive 
performance (MMSE, Stroop, Letter Digit Substitution Task (LDST) and 12-Picture Learning Test 
(12-PLT immediate (i) and delayed recall (d)). Error bars indicate standard error (SE). P value 
indicates p for trend of mean handgrip strength in tertiles of test scores (linear regression analysis 
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longitudinal analysis of this association. Better cognitive performance was 
associated with a lower decline in handgrip strength over time (all, P<.001). 
Adjustment for possible confounders, including physical activity scores did not 
change the results (all, P< .02, model 3). 
Table 2   Cross-sectional association between cognitive performance and 






β (SE) P 
value
β (SE) P 
value
MMSE(points)
Model 1: Adj. for sex, height, weight 0.43 (0.05) <0.001 0.42 (0.07) <0.001
Model 2: as 1 and income, education, 
prescription medication and GDS
0.22 (0.11) 0.035 0.41 (0.14) 0.003
Model 3: as 2 and physical activity score 0.19 (0.10) 0.073 0.36 (0.14) 0.008
Stroop, trial 3 (seconds)
Model 1: Adj. for sex, height, weight -0.02 (0.01) 0.031 -0.02 (0.01) 0.859
Model 2: as 1 and income, education, 
prescription medication and GDS
-0.01 (0.01) 0.248 0.03 (0.02) 0.810
Model 3: as 2 and physical activity score -0.01 (0.01) 0.530 0.01 (0.01) 0.431
LDST (correct answers)
Model 1: Adj. for sex, height, weight 0.18 (0.04) <0.001 0.24 (0.07) <0.001
Model 2: as 1 and income, education, 
prescription medication and GDS
0.16 (0.04) <0.001 0.24 (0.07) 0.001
Model 3: as 2 and physical activity score 0.14 (0.04) 0.001 0.21 (0.07) 0.004
12-PLT Immediate recall (pictures)
Model 1: Adj. for sex, height, weight 0.16 (0.05) 0.001 0.23 (0.06) <0.001
Model 2: as 1 and income, education, 
prescription medication and GDS
0.12 (0.05) 0.014 0.22 (0.06) 0.001
Model 3: as 2 and physical activity score 0.09 (0.05) 0.059 0.19 (0.06) 0.003
12-PLT Delayed recall (pictures)
Model 1: Adj. for sex, height, weight 0.29 (0.10) 0.005 0.44 (0.13) 0.001
Model 2: as 1 and income, education, 
prescription medication and GDS
0.21 (0.10) 0.048 0.42 (0.13) 0.001
Model 3: as 2 and physical activity score 0.17 (0.10) 0.109 0.34 (0.13) 0.010
Abbreviations: Kg, kilogram; β, estimate; SE, standard error; MMSE, Mini Mental State Examination; 
GDS, Geriatric Depression Score, 15 items; LDST, Letter Digit Substitution Task; 12-PLT, 12-Picture 
Learning Test.
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6.4.4  Longitudinal association between baseline handgrip strength 
and decline in cognitive performance 
Table 4 shows the results of the longitudinal analysis of the association between 
baseline handgrip strength and decline in cognitive performance. Baseline 
Table 3   Association between baseline cognitive performance at age 85 years 
and decline in handgrip strength between age 85 years and 89 years 
(n = 307)
Decline in  
handgrip strength (Kg)
β (SE) P value
MMSE (points)
Model 1: Adj. for sex, height, weight, baseline grip strength -0.25 (0.06) <0.001
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.30 (0.10) 0.012
Model 3: as 2 and physical activity score -0.27 (0.06) 0.015
Stroop, trial 3 (seconds)
Model 1: Adj. for sex, height, weight, baseline grip strength 0.03 (0.01) 0.001
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
0.03 (0.01) 0.006
Model 3: as 2 and physical activity score 0.02 (0.01) 0.009
LDST (correct answers)
Model 1: Adj. for sex, height, weight, baseline grip strength -0.16 (0.04) <0.001
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.16 (0.04) <0.001
Model 3: as 2 and activity score -0.16 (0.04) <0.001
12-PLT, immediate recall (pictures)
Model 1: Adj. for sex, height, weight, baseline grip strength -0.18 (0.05) <0.001
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.17 (0.05) <0.001
Model 3: as 2 and physical activity score -0.17 (0.05) <0.001
12-PLT, delayed recall (pictures)
Model 1: Adj. for sex, height, weight, baseline grip strength -0.38(0.10) <0.001
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.35 (0.10) 0.001
Model 3: as 2 and physical activity score -0.35(0.10) 0.001
Abbreviations: Kg, kilogram; β, estimate; SE, standard error; MMSE, Mini Mental State Examination; 




handgrip strength was not associated with a decline in cognitive performance 
(all, P> .05), except for MMSE (P= .007). 
Table 4   Association between baseline handgrip strength  and change in 
cognitive performance between age 85 and 89 years (n = 307)
Change in cognitive 
performance according 
to handgrip strength 
(Kg) at age 85 years 
β (SE) P value
MMSE (points)
Model 1: Adj. for sex, height, weight, baseline MMSE -0.11 (0.05) 0.018
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.14 (0.05) 0.004
Model 3: as 2 and physical activity score -0.13 (0.05) 0.007
Stroop, trial 3 (seconds)
Model 1: Adj. for sex, height, weight, baseline Stroop test -0.43 (0.29) 0.151
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.51 (0.31) 0.099
Model 3: as 2 and physical activity score -0.53 (0.31) 0.092
LDST (correct answers)
Model 1: Adj. for sex, height, weight, baseline LDST -0.05 (0.05) 0.280
Model 2: as 1 and income, education, prescription medication 
and baseline GDS†
-0.04 (0.05) 0.384
Model 3: as 2 and physical activity score -0.04 (0.05) 0.400
12-PLT, immediate recall (pictures)
Model 1: Adj. for sex, height, weight, baseline 12-PLT 
immediate recall
-0.08 (0.06) 0.224
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.09 (0.06) 0.174
Model 3: as 2 and physical activity score -0.09 (0.06) 0.158
12-PLT, delayed recall (pictures)
Model 1: Adj. for sex, height, weight, baseline 12-PLT delayed 
recall
-0.02 (0.03) 0.454
Model 2: as 1 and income, education, prescription medication 
and baseline GDS
-0.03 (0.03) 0.305
Model 3: as 2 and physical activity score -0.03 (0.03) 0.371
Abbreviations: Kg, kilogram; β, estimate; SE, standard error; MMSE, Mini Mental State Examination; 
GDS, Geriatric Depression Score, 15 items; LDST, Letter Digit Substitution Task; 12-PLT, 12-Picture 
Learning Test.
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6.5 Discussion
The aim of the present study was to analyze the temporal relationship between 
cognitive performance and handgrip strength in a population based cohort of 
oldest old people. Cognitive performance and handgrip strength were significantly 
correlated in the cross sectional analysis in older people. However, in the 
longitudinal analysis we found that better baseline cognitive performance, in 
particular attention, processing speed and memory function, was associated 
with slower decline in handgrip strength, whereas low baseline handgrip strength 
was not associated with an accelerated decline in cognitive performance. 
Based on these finding we conclude that cognitive decline precedes the onset 
of muscle weakness. 
Most of the previous longitudinal studies analyzing the relationship between 
cognitive performance and functional ability were based on selected populations 
[8, 10-14] or restricted to a particular ethnic group [8, 11] or gender [11, 16]. 
To the best of our knowledge only one recent prospective study has investigated 
the temporal relationship between handgrip strength and cognitive decline in 
elderly women and concluded that cognitive decline preceded handgrip strength 
decline [16]. However, in the aforementioned study cognitive performance 
included only global function, measured by a Modified MMSE in subjects being 
on average 15 years younger than the subjects in our study. In our longitudinal 
analysis in the oldest old we found that global cognitive performance (measured 
by MMSE) was associated with handgrip strength decline and vice versa. 
Therefore, in oldest old subjects global cognitive performance and handgrip 
strength are possibly both reflecting decline in general health in old age. 
At age 85 years, attention, processing speed, and memory were all significantly 
associated with handgrip strength decline over time. To our knowledge we 
are the first to report on the temporal association between these cognitive 
measures and muscle strength decline. Others have found attention and 
processing speed to be associated with impairment in activities of daily living 
[32] and lower extremity function [33-36]. Neuroimaging studies have shown 
that skilled hand movement and grip force control involves not only cortical 
motor areas, but also higher cognitive performance, as reflected by activity in 
the frontal and parietal cortical regions [19]. A study comparing young and old 
subjects using functional neuroimaging when performing simple hand 
movement observed that elderly showed increased cognitive control of motor 
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performance. This increased cognitive control was reflected by the activation 
of frontal lobe areas, and very complex movement areas that are involved in 
inhibitory cognitive control [18].
A recent study investigated neuropathology in a community based cohort of 
oldest old people without cognitive impairment at the time of death [37]. In 
40% of the subjects Alzheimer disease neuropathology was found, furthermore 
ischemic infarction was present in 40%. This finding shows that extensive 
neuropathology is a common finding in community dwelling oldest old without 
signs of clinical dementia and it seems likely that this might influence the 
cognitive control of movement and muscle strength.
The present study has several strengths for studying the relationship between 
cognitive performance and muscle strength in oldest old subjects. The Leiden 
85-plus Study is a longitudinal population based cohort study with extensive 
measures for health and functioning. The results can be generalized to western 
populations of oldest old people. Furthermore, the longitudinal design with 
repeated measurements of diverse items of health allowed us to demonstrate 
a temporal association. A limitation of our study is that neuroimaging was not 
available. 
In conclusion we found that better cognitive performance was associated with 
better muscle strength and a slower decline in muscle strength. This suggests 
that cognitive decline precedes muscle weakness. It seems likely that in elderly 
subjects cognitive control of movement and muscle strength are affected by 
cerebral neuropathology. Cognitive decline in elderly subjects should make 
clinicians vigilant for muscle weakness in the near future. Further clinical 
research is needed to assess suitable interventions. 
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Candidate determinants of 
muscular vitality in oldest old people

7
Higher blood pressure is 
associated with higher handgrip 
strength in the oldest old
Taekema DG, Maier AB, Westendorp RGJ, de Craen AJM 




Background: Ageing is associated with progressive loss of muscle strength. 
Muscle tissue is vascularized by an elaborate vascular network. There is 
evidence that blood pressure (BP) is associated with muscle function in middle 
age. It is unknown how BP associates with muscle function in oldest old people. 
We studied the association between BP and handgrip strength in middle and 
old age. 
Method: BP was measured automatically in middle-aged subjects and with a 
mercury sphygmomanometer in the oldest old. Handgrip strength was measured 
with a handgrip strength dynamometer. Cross-sectional measurements of 
handgrip strength and BP were available for 670 middle-aged subjects (mean 
63.2 ± 6.6 years) and 550 oldest old subjects (all 85 years). Prospective data 
were available for oldest old subjects only with a 4-year follow-up at 89 years. 
The association between BP and handgrip strength was analyzed by linear 
regression analysis.
Results: in middle-aged subjects BP and handgrip strength were not statistically 
significantly associated. In oldest old subjects, higher systolic BP (SBP), mean 
arterial pressure (MAP) and pulse pressure (PP) were associated with higher 
handgrip strength after adjusting for comorbidity and medication use (all 
P< 0.02). Furthermore, in oldest old subjects change in SBP, MAP, PP after 4 years 
was associated with declining handgrip strength (all, P< 0.05). 
Conclusion: in oldest old higher blood pressure is associated with better 
muscle strength. Further study is necessary to investigate if blood pressure is 
a potential modifiable risk factor for prevention of age associated decline in 
muscle strength. 
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7.2 Introduction
Ageing is associated with a decline in muscle mass, commonly referred to as 
sarcopenia [1-3]. Sarcopenia is a major determinant of strength loss in the 
elderly. Poor muscular strength is in turn associated with adverse outcomes, 
such as physical disability and mortality [4, 5]. Depending on the definition 
used, the prevalence of sarcopenia is reported to be as high as 60% in the 
general oldest old population (over 85 years) [1]. By 2050, the oldest old will 
account for one-fifth of all older persons globally [6]. In view of the detrimental 
effects sarcopenia may have on the quality of life and survival of our ageing 
societies, research into its pathogenesis and etiology is mandatory for optimization 
of preventive and therapeutic strategies. 
Skeletal muscle tissue is vascularized by an elaborate microvascular network 
of arterioles and venules and makes up 30-40% of body mass. During strenuous 
exercise, skeletal blood flow is regulated by increasing cardiac output and 
reducing vascular resistance in the feeding arteries and arterioles of skeletal 
muscle [7-9]. Ageing has been associated with a reduced activity tolerance 
attributed to changes in this skeletal muscle blood flow [10-13]. Blood pressure 
(BP) is a biomarker of atherosclerosis and might be associated with skeletal 
muscle tissue damage, comparable to kidney failure and dementia [7, 14-17].
A commonly used proxy for global muscle strength is handgrip strength [18, 
19]. Isometric handgrip strength exercise has been associated with lower 
resting diastolic BP [20]. This finding shows that resistance training limited to 
the hand only is associated with changes in systemic BP. Furthermore, lower 
handgrip strength was associated with higher resting BP in a large population 
based sample of men and women (mean age 66 years) [21]. Body composition 
measures such as higher BMI and waist circumference, associated with lower 
lean body mass, have been associated with higher BP in middle-aged volunteers 
[22]. 
In contrast to young and middle-aged subjects, recent studies in oldest old 
subjects have shown that higher BP is associated with preservation of renal 
function [23] and better cognition [24-26]. Hence, these are major health 
conditions that significantly depend on vascular function. Possibly the 
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association between BP and handgrip strength also changes in different age 
groups similar to our findings for cognitive function [24].
We investigated the hypothesis that higher BP is associated with lower 
handgrip strength in middle age and that in oldest old higher BP is associated 
with higher handgrip strength. We studied the association between BP and 
handgrip strength, as a proxy of muscle strength, in two independent populations 
of different ages, i.e middle-aged and oldest old subjects. 
7.3 Method
7.3.1 Subjects
In the Leiden Longevity Study, 420 families were recruited consisting of 
long-lived Caucasian siblings together with their middle-aged offspring and 
the partners thereof [27]. There were no other inclusion criteria for the 
offspring, other than being offspring of the nonagenarian siblings or being the 
partner of the offspring for the group of partners. Our study includes the cross-
sectional baseline sample of the middle-aged offspring and their partners 
(n= 670). All subjects visited the study center where all measurements were 
performed.
The Leiden 85-plus Study is a community-based longitudinal study of all 
inhabitants of the city of Leiden, the Netherlands [28]. Enrollment took place 
between 1997 and 1999. All inhabitants who reached the age of 85 years, 
including nursing home residents, were eligible to participate (n= 550). 
Subjects were visited at their place of residence where all measurements were 
performed. Annual follow up visits were performed until death or age 90 
years. 
In both studies there were no selection criteria on health or demographic 
 characteristics [29, 30]. The Medical Ethical Committee of the Leiden University 
Medical Centre approved both studies. Informed consent was obtained from 
all subjects. In case of severe cognitive impairment a guardian gave informed 
consent.
7.3.2 Blood pressure
In the Leiden Longevity Study, BP was measured at one time point. BP was 
measured twice in each participant at the beginning of the visit at the study 
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center and twice again three hours later at the end of the visit. BP was measured 
using an automated BP device, Omron 705CP (Omron, Matsusaka Co. Ltd., 
Matsusaka-City, Japan) in a seated position after at least 5 minutes of rest and 
no vigorous exercise in the preceding 30 minutes. For the analyses we used the 
means of the second and fourth measured systolic BP (SBP) and diastolic BP 
(DBP). 
In the Leiden 85-plus Study, BP was measured once at two time points. BP was 
measured during the home visits. Subjects were visited twice, with a mean 
intervening period of 2 weeks, at ages 85 and 89 years. For the analysis we 
used the means of the two measurements of SBP and DBP. BP was measured, 
using a mercury sphygmomanometer, in a seated position after at least 5 
minutes of rest and no vigorous exercise in the preceding 30 minutes. The 
systolic value was measured at the first Korotkoff sound, and the diastolic 
value was measured at the fifth Korotkoff sound [23]. Mean arterial pressures 
(MAP), the steady component of BP, was calculated as 1/3(SBP) + 2/3(DBP) in 
both studies [29]. Pulse pressure (PP), the pulsatile component of BP, was 
calculated as SBP – DBP in both studies [29].
7.3.3 Handgrip strength
Handgrip strength was used as a proxy of muscle strength [18, 19]. In both 
studies handgrip strength was measured with a Jamar hand dynamometer 
(Sammons Preston Inc, Bolingbrook, IL). Handgrip strength and BP were 
measured on the same day in both studies. All subjects were asked to stand up 
and hold the dynamometer in the dominant hand with the arm parallel to the 
body without squeezing the arm against the body. The width of the handle was 
adjusted to the size of the hand to make sure that the middle phalanx rested on 
the inner handle. The participant was allowed to perform one test trial. After 
this, three trials followed and the best score was taken for analysis. Handgrip 
strength was expressed in kilograms. In the Leiden Longevity Study handgrip 
strength was measured at one time point. In the Leiden 85-plus Study handgrip 
strength was measured at ages 85 and 89 years.
7.3.4 Potential confounders
Anthropometric data were collected for all subjects. Body mass index (weight/
height2) was computed for each subject Information on common chronic 
diseases and medication use was obtained from the general practitioner, 
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pharmacist’s records, and blood sample analysis. Chronic diseases included 
diabetes mellitus, chronic obstructive pulmonary disease, rheumatoid arthritis 
and osteoarthrosis, malignancy, myocardial infarction, stroke, and hyper tension. 
Comorbidity was defined as a sum score of all chronic diseases per subject, 
excluding hypertension. A sum score for comorbidity might underestimate the 
impact of comorbidity on health status, therefore the total number of 
prescription medications was also included. Smoking habits were recorded by 
self report. Cognitive functioning was measured with the Mini Mental State 
Examination (MMSE) [30].
7.3.4 Statistical analysis
The association between comorbidity and handgrip strength was analyzed by 
linear regression analysis, adjusted for gender, height and weight, and age 
for middle-aged subjects. The association between BP and handgrip strength 
was analyzed by linear regression analysis by using 4 models. In model 1 the 
analysis was adjusted for gender, height, weight, and smoking. In middle-aged 
subjects age was included in model 1, in oldest old subjects cognition (MMSE) 
was included in model 1. Model 2 was adjusted as model 1 with further 
adjustments for number of chronic diseases, except cardiovascular disease 
and hypertension. Model 3 was adjusted as model 2 with further adjustments 
for the cardiovascular diseases, except hypertension. Model 4 was adjusted as 
model 3 with further adjustments for number of medication (including anti-
hypertensive medication) as a proxy for the severity of chronic illness. For the 
prospective analysis in the oldest old subjects, all models were additionally 
adjusted for BP at baseline (BP85 + BP89 /2). The association between tertiles 
of BP and handgrip strength was analyzed by linear regression analysis 
adjusted for gender, height, weight, and when appropriate age. 
To test if antihypertensive medication influenced the association between BP 
and handgrip strength, BP were divided into tertiles to form groups with 
similar BP. The difference in handgrip strength between users and non-users 
of antihypertensive medication was tested by linear regression. Data on class 
of medication was available for the oldest old subjects. The medication was 
divided into four classes; ACE inhibitors, beta blockers, diuretics and calcium 
antagonists. Mean values of handgrip strength between classes of medication 
were assessed by ANOVA (analysis of variance).
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In the oldest old subjects BP at 85 years was ranked in tertiles. Cut points for 
SBP were: lowest 110-147mmHg, middle 148–162 mmHg, highest 163–215 
mmHg. Cut points for DBP were: lowest 47-72mmHg, middle 73–81 mmHg, 
highest 82–115 mmHg. Cut points for MAP were: lowest 70-98mmHg, middle 
98–107 mmHg, highest 108–146 mmHg. Cut points for PP were: lowest 45-71 
mmHg, middle 72–84 mmHg, highest 84–131 mmHg. SPSS 17.0 for Windows 




Baseline characteristics of the study subjects are presented in table 1. Mean 
age of the middle-aged subjects was 63.2 ± 6,6 years and mean age of the oldest 
old subjects was exactly 85 years. 
In middle-aged subjects higher BMI was associated with higher systolic and 
diastolic BP (both, P< 0.001) and higher handgrip strength (p= 0.002). 
In oldest old subjects BMI was not associated with blood pressure (P> 0.100) 
and handgrip strength (P= 0.102). Moreover, in middle-aged subjects comorbidity 
was significantly associated with lower handgrip strength (-1.0 kg for each 
additional comorbidity, P= 0.04). In oldest old subjects comorbidity was also 
associated with lower handgrip strength (-0.7 kg for each additional comorbidity, 
P= 0.02). In both cohorts no differences were found in mean handgrip strength 
between users and non-users of antihypertensive medication within tertiles 
of blood pressure (data not shown, all, P> 0.05). 
7.4.2 Blood pressure and handgrip strength, cross-sectional associations 
The results for middle-aged subjects are presented in table 2. Higher mean 
DBP was associated with a higher handgrip strength (0.06 kg higher per 
1 mmHg increase in pressure, model 1 and 4, P< 0.05). After adjustment for 
chronic diseases (model 2 and model 3), the observed significance was lost. 
No associations were found between mean SBP, PP, MAP, and handgrip strength 
in middle-aged subjects. There were no differences between offspring and 
partners in the association between blood pressure and handgrip strength 
(data not shown). 
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In oldest old subjects higher mean SBP, MAP and PP were all associated with 
higher handgrip strength (table 3). After adjusting for chronic diseases (model 
2 and 3), none of the observed associations changed (all, P≤ 0.01) in oldest old 
subjects. Further adjustment for the number of medications did not change the 
results (model 4). DBP was not associated with handgrip strength at 85 years 
after adjusting for chronic diseases and number of medication. At 89 years no 
significant associations were found for DBP. There were no differences in mean 
handgrip strength dependent on class of medication in the group of users and 
non-users of antihypertensive medication (all, P> 0.100, data not shown). 
Table 1   Baseline characteristics of study subjects
Middle aged Oldest old
N= 670 N= 550
Age, mean (SD)*, years 63.2 (6.6) 85
Women, number (%) 325 (50.0) 363 (66.0)
Height, mean (SD)*, m† 1.72 (9.1) 1.60 (10.6)
Weight, mean (SD)*, Kg‡ 79.0 (13.6) 70.0 (12.8)
Smoking, number (%) 84 (12.7) 84 (16.8)
MMSE§, median, IQR**, points - 26 (22-28)
Blood pressure, mean (SD)*, mmHg††
Systolic pressure (SBP) 141.5 (20.2) 155.6 (18.4)
Diastolic pressure (DBP) 82.5 (10.0) 76.9 (9.4)
Mean arterial pressure (MAP) 102.2 (12.4) 103.2 (12.4)
Pulse pressure (PP) 59.0 (15.0) 78.7 (15.2)
Handgrip strength (Kg)‡
Women, mean (SD)* 29.7 (5.7) 19.0 (5.0)
Men, mean (SD)* 46.8 (8.1) 31.0 (8.0)
Chronic diseases, number (%)
Diabetes Mellitus 41 (6.3) 87 (15.8)
COPD‡‡ 24 (3.7) 64 (11.6)
RA/OA§§ 5 (0.7) 178 (32.5)
Malignancy 45 (6.7) 99 (18.1)
Myocardial infarction 14 (2.1) 128 (23.3)
Stroke 16 (2.47) 52 (9.5)
Hypertension 166 (24.6) 218 (39.6)
* SD= standard deviation; † m= meter; ‡ Kg= kilogram;  § MMSE = Mini Mental State Examination; ** 
Interquartile Range; †† mmHg= millimeters of mercury; ‡‡ COPD = Chronic Obstructive Pulmonary 
Disease; §§ RA/OA= rheumatoid arthritis/osteoarthrosis
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Figure 1 shows mean handgrip strength according to tertile of BP in oldest old 
subjects. Higher mean BP is significantly associated with higher mean handgrip 
strength after adjusting for sex, height, weight, smoking and MMSE (all, P for 
trend < 0.05).
7.4.3 BP and handgrip strength during follow up in oldest old subjects
At age 89 years 196 (35.6 %) subjects had died and 33 (6 %) refused further 
participation in the study. Mean SBP and DBP declined 5.8 mmHg (SD 17.9) and 
Table 2   Blood pressure as determinant of handgrip strength in middle aged 
subjects
Blood pressure  Handgrip strength (Kg)*
N = 670
Β † SE‡ P value
Systolic pressure (SBP, mmHg)§
Model 1: adjusted for  age, sex, height, weight, smoking 0.003 0.01 0.802
Model 2: as model 1 and chronic diseases** 0.004 0.01 0.749
Model 3: as model 2 and cardiovascular diseases†† 0.003 0.01 0.810
Model 4: as model 3 and number of medication‡‡ 0.003 0.01 0.858
Diastolic pressure (DBP, mmHg)§
Model 1: adjusted for  age, sex, height, weight, smoking 0.06 0.03 0.014
Model 2: as model 1 and chronic diseases** 0.04 0.03 0.120
Model 3: as model 2 and cardiovascular diseases†† 0.04 0.03 0.128
Model 4: as model 3 and number of medication‡‡ 0.06 0.03 0.028
Mean arterial pressure (MAP, mmHg)§
Model 1: adjusted for  age, sex, height, weight, smoking 0.03 0.02 0.140
Model 2: as model 1 and chronic diseases** 0.02 0.02 0.311
Model 3: as model 2 and cardiovascular diseases†† 0.02 0.02 0.340
Model 4: as model 3 and number of medication‡‡ 0.03 0.02 0.200
Pulse pressure (PP, mmHg)§
Model 1: adjusted for  age, sex, height, weight, smoking -0.02 0.02 0.169
Model 2: as model 1 and chronic diseases** -0.01 0.02 0.514
Model 3: as model 2 and cardiovascular diseases†† -0.01 0.02 0.458
Model 4: as model 3 and number of medication‡‡ -0.02 0.02 0.213
* Kg= kilogram; † β= estimate; ‡ SE= standard error; § mmHg= millimeters of mercury; ** Including 
diabetes mellitus, chronic obstructive pulmonary disease, rheumatoid arthritis & osteoarthrosis, 
and malignancy; § mmHg= millimeters of mercury; †† Including myocardial infarction and stroke, 
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5.4 mmHg (SD 8.8) respectively (both, P< 0.001) from ages 85 to 89 years. Over 
time the decline of the MAP was 5.5 mmHg (mean, SD 10.3, P< 0.001). Pulse 
pressure did not significantly change during follow up. Handgrip strength 
declined significantly from ages 85 to 89 years. In oldest old men, mean hand - 
grip strength declined during follow up with 6.3 kg (SD 5.4, P< 0.001). In oldest 
old women, mean handgrip strength declined 3.4 kg (SD 4.2 kg, P< 0.001) 
during follow up. 
Table 4 shows the association between change in BP and change in handgrip 
strength from 85 to 89 years. During follow up, declining SBP and MAP were 
associated with a higher decline in handgrip strength (0.04 kg and 0.06 kg 
decline in handgrip strength per 1 mmHg decline in SBP and MAP respectively, 
both P≤ 0.100). This means that per 10 mmHg decline in SBP or MAP, handgrip 
strength declined 0.4 kg and 0.6 kg, respectively. These results remained 
unchanged after adjusting for comorbidity (models 2 and 3, all P< 0.05). After 
Figure 1   Mean handgrip strength according to tertile of resting blood 
pressure in oldest old subjects (85 years)
Systolic blood pressure (SBP: lowest tertile 110- 147 mmHg, middle tertile 148– 162 mmHg, highest 
tertile 163– 215 mmHg. Diastolic blood pressure (DBP): lowest tertile 47.00 - 72.00 mmHg, middle 
tertile 73 – 81 mmHg, highest tertile 82 – 115 mmHg. Mean arterial pressure (MAP): lowest tertile 
70 - 98 mmHg, middle tertile 98 – 107 mmHg, highest tertile 108 – 146 mmHg. Pulse pressure (PP): 
lowest tertile 45 - 71 mmHg, middle tertile 72 – 84 mmHg, highest tertile 84 – 131 mmHg. Error bars 
indicate standard error (SE). P value indicates p for trend of mean handgrip strength in tertiles of 
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adjustment for number of medications associations remained similar for decline 
in SBP (model 4, P= 0,023), but were lost for decline in MAP (model 4, P= 0,058). 
Decline in PP was significantly associated with a higher decline in handgrip 
strength after adjustment for all measured potential confounders (0.04 kg 
decline in handgrip strength per 1 mmHg decline in PP, P= 0.049, model 4). 
No significant association was observed for change in diastolic pressure and 
change in handgrip strength during follow up.
7.5 Discussion
In our prospective population-based study of oldest old subjects we found a 
positive association between SBP, DBP and PP and handgrip strength in oldest 
old subjects. Furthermore, we found that declining SBP, MAP and PP were 
associated with a decline in handgrip strength during follow up. BP was not 
associated with handgrip strength in the middle-aged subjects.
We hypothesized that higher BP was associated with lower handgrip strength 
in middle-aged subjects, because higher BP has been associated with lower 
handgrip strength and body composition in earlier cross-sectional studies [21, 
22]. However, our cross-sectional analysis showed that in middle-aged subjects, 
lower handgrip strength was not significantly associated with higher BP. 
In the oldest old subjects, however higher BP was associated with higher 
handgrip strength. Furthermore, declines in SBP and MAP were associated 
with a decrease in handgrip strength in the oldest old during follow up. Earlier 
we have shown that higher BP was associated with better renal function [23] 
and cognition [24] over time in oldest old subjects of the Leiden 85-plus Study. 
Euser et al. studied age related differences in BP and changes in cognitive 
function [24] . Higher BP was a risk factor for cognitive decline up to the age of 
75 years, but surprisingly in oldest old subjects higher BP was associated with 
better cognitive function. Others have also reported on the association of 
higher BP and better cognitive function in very old age [2].
How can we explain the associations between higher BP and better muscular 
function in the oldest old? Peripheral vascular resistance increases with 
chronological age due to a reduced sympatholysis which results in an elevated 
sympathetic tone [31, 32]. Second, morphological changes to the arteriolar 
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network contribute to higher vascular resistance [8]. Third, ageing is associated 
with a reduced capacity in vasodilation caused by changes in endothelium 
dependent pathways in animal models [33-36]. Maybe increased vascular 
resistance during the ageing process requires higher pressure as a mechanism 
to maintain tissue perfusion as a means to prevent further ischaemic end 
organ damage in kidney, brain and skeletal muscle. Another cause for higher 
BP in elderly could be the age associated increase in cortisol levels [37, 38]. But 
since higher cortisol levels associate with lower handgrip strength, this does 
not explain our finding of higher handgrip strength [38]. 
Moreover, another possible explanation could be that BP associates with the 
age associated loss of lean mass without the presence of a causal relationship 
[2, 3]. Evidence of such a mutual pathway was found in middle-aged men for 
mid-thigh cross-sectional areas and brachial ankle pulse wave velocity [39]. 
Considering the numerous factors that have been associated with sarcopenia 
it is also possible that another unknown factor explains the positive association 
between handgrip strength and BP [1].
This study has several strengths for studying the association between BP and 
handgrip strength. The Leiden 85-plus Study is a longitudinal population 
based cohort study with extensive measures for health and functioning 
without selection criteria on health or demographic characteristics. Therefore 
the results can be generalized to the western population of oldest old. 
Furthermore, the longitudinal design of the Leiden 85-plus Study with 
repeated measurements of both BP and handgrip strength allowed us to 
demonstrate the longitudinal association between the two parameters in the 
oldest old subjects. A weakness of this study is that only cross-sectional 
associations were available in the Leiden Longevity Study for the present 
analysis, which makes causal inference difficult. Also no direct measurements 
of muscle mass were available. 
7.6 Conclusion
This study found a relationship between 4-year changes in handgrip strength 
and resting SBP, DBP and PP in oldest old people. To our knowledge this is the 
first study to report on the prospective relationship between BP and muscle 
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strength in oldest old subjects. The results of the Hyvet study [40] provide 
evidence that lowering BP is beneficial for prevention of cardiovascular disease 
and lowering mortality risk in healthy elderly. In contrast, we found that higher 
BP is positively associated with better outcome in old age, such as renal function 
[23], cognition [24], and now muscle strength. Further research is needed into 
the implications of hypertension and antihypertensive treatment in the general 
population of oldest old. 
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Objective: In ageing populations poor handgrip strength has been associated 
with physical disability and mortality. Insulin-like Growth Factor-1 (IGF-1) is 
an important mediator of muscle growth and regeneration affecting muscle 
function. We studied the relation between circulating levels of IGF-1, its binding 
protein-3 (IGFBP-3), and handgrip strength and physical performance in 
middle-aged and oldest old subjects. 
Design: Cross sectional analysis in two different cohorts composed of middle- 
aged (n= 672, mean 63.9 ± 6.7 years) and oldest old subjects (n= 272, all 89 
years). 
Methods: Handgrip strength, functional performance and ability and serum 
levels of IGF-1 and IGFBP-3 were measured in all subjects and analyzed by 
linear regression for men and women separately. 
Results: IGF-1 and IGFBP-3 levels declined with chronological age and were 
positively associated with handgrip strength in middle-aged and oldest old 
women (both, P< 0.05), but not in men of either age group. Furthermore, higher 
IGF-I serum levels were associated with slower walking speed in oldest old 
men (P= 0.012) and serum levels of IGFBP-3 were positively associated with 
activities of daily living in the oldest old women (P= 0.002). 
Conclusion: The significant relation between IGF-1 levels and muscle strength 
found in women but not in men suggests a gender-specific influence of IGF-1 on 
muscle strength. Further studies are necessary to test the relationship with 
physical performance. 
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8.2 Introduction
Ageing is associated with a decline in muscle mass, commonly referred to as 
sarcopenia. Sarcopenia is a major determinant of muscle strength loss in the 
elderly. Poor muscular strength is in turn associated with adverse outcomes, 
such as physical disability and mortality [1-3]. Depending on the definition 
used, the prevalence of sarcopenia is reported to be as high as 60% in the 
general oldest old population, being subjects older than over 85 years of age 
[4]. by 2050, oldest old subjects will account for one-fifth of all older persons 
globally [5]. In view of the detrimental functional effects sarcopenia may have 
on the quality of life and survival of our ageing societies, research into its 
etiology is important for optimization of preventive and therapeutic strategies. 
The pathophysiology of sarcopenia is complex and involves interplay of multiple 
factors including chronic diseases, inflammatory, metabolic, nutritional and 
hormonal factors [4]. With regard to hormonal factors, evidence increasingly 
suggests an association between age-dependent decline in levels of growth 
hormone (GH) and Insulin-like Growth Factor-1 (IGF-1), the major mediator of 
GH action, with unfavorable changes in body composition with age [6, 7]. 
Moreover, the reduction in physical activity also contributes to the decline in 
GH secretion and alteration in body composition during ageing [6]. Both GH 
and IGF-1 have important anabolic effects on skeletal muscle tissue. IGF-1 has 
been shown to stimulate muscle cell proliferation and differentiation, facilitate 
muscle protein synthesis and inhibit its degradation [8]. 
Previous studies have assessed the association between IGF-1 and IGF binding 
protein 3 (IGFBP-3) and functional outcome in older people. Low serum levels 
of IGF-I and IGFBP-3 were reported to be associated with poorer muscular 
strength, walking speed, mobility tasks, various physical performance and 
all-cause mortality in the elderly [9-12]. GH therapy has been associated with 
increased lean body mass and decreased fat mass [13-15], but evidence is still 
lacking on its effectiveness in improving muscle function and overall physical 
performance in the old. However, aforementioned studies were not consistent 
in their findings and did not include the group of oldest old subjects. 
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More research is needed to assess the association between these hormonal 
factors and muscle function, overall physical performance and disability. We 
assessed this relationship in two different age groups composed of middle-aged 
and oldest old subjects. We hypothesized that lower levels of IGF-1 are 
associated with lower muscle strength in middle-aged and oldest old subjects, 
and that lower levels of IGF-1 are associated with impaired physical 
performance and disability in oldest old subjects.
8.2 Method
8.2.1 Subjects
Data for the middle-aged and oldest old subjects were obtained from the 
Leiden Longevity Study and Leiden 85-plus Study respectively. In the Leiden 
Longevity Study, 420 families were recruited consisting of long-lived Caucasian 
siblings together with their middle-aged offspring and the partners thereof 
[16]. This study included 672 of the middle-aged offspring and their partners. 
All subjects visited the study center where measurements were performed. 
The Leiden 85-plus Study is a community-based prospective follow-up study of 
inhabitants of the city of Leiden, the Netherlands [17]. Enrolment took place 
between 1997 and 1999. All inhabitants who reached the age of 85 years were 
eligible to participate (n= 599). Subjects were visited annually at their place of 
residence where various tests were performed. Follow-up continued until 
death or 90 years of age. The current study included 272 oldest old subjects 
who were alive at age 89 years. There were no selection criteria on health or 
demographic characteristics in both studies [16, 17]. The Medical Ethical 
Committee of the Leiden University Medical Centre approved both studies. 
Informed consent was obtained from all subjects. In case of severe cognitive 
impairment a guardian gave informed consent.
8.2.2 Subject characteristics and possible confounders
Anthropometric data were collected for all subjects. At baseline, information 
on common chronic diseases and medication use was obtained from the general 
practitioner, pharmacist’s records and blood sample analysis. Information on 
menopausal state and past and current use of hormone replacement therapy in 
the middle-aged women was assessed by a questionnaire at baseline. The chronic 
123
CIRCuLATING LEvELS OF IGF-1 ARE ASSOCIATED WITH MuSCLE STRENGTH IN WOMEN 
8
diseases recorded were diabetes mellitus, chronic obstructive pulmonary 
disease, malignancy, myocardial infarction, stroke and hypertension. For each 
subject, a sum score of chronic diseases (defined as comorbidity) was assigned. 
8.2.3 Serum parameters
Since systemic inflammation is negatively associated with serum levels of IGF-1 
[18], serum C-reactive protein (CRP) levels were measured as a proxy for 
systemic inflammation. Serum levels of IGF-1, IGFBP-3 and CRP were determined 
in the middle-aged subjects and at age 89 years in the oldest old subjects. In both 
studies, IGF-1 and IGFBP-3 were determined using the automated Immulite 2500 
from DPC (Los Angeles, CA, USA). CRP was measured with a standard, fully 
automated P800 Modular system (Roche, Boehringer Mannheim, Germany) 
with a sensitivity ranging from 1 mg/L in the oldest old subjects to 0.6 mg/L in 
the middle-aged subjects. The increased sensitivity in the middle-aged subjects 
is explained by improvements to the CRP assay in later models of the analyzer. 
8.2.4 Handgrip strength
Handgrip strength was used as a proxy for global muscle strength [19, 20] and 
was measured using a Jamar hand dynamometer (Sammons Preston Inc, 
Bolingbrook, IL) to the nearest kilograms. Measurement of handgrip strength 
is a reliable instrument and has been tested in different age groups, including 
oldest old subjects [21-23]. All subjects were instructed to maintain an upright 
standing position, arms down by the side, and holding the dynamometer in the 
dominant hand without squeezing the arm against the body. The width of the 
dynamometer’s handle was adjusted to the hand size of the subjects such that 
the middle phalanx rested on the inner handle. Subjects were allowed to 
perform one test trial, followed by three trials and the best measure was taken 
for analysis. Handgrip strength was measured at one time point in the 
middle-aged subjects and at age 89 years in the oldest old subjects. 
8.2.5 Measurements of functional ability in oldest old subjects
Functional ability was measured only in the group of oldest old subjects. 
Competence in the activities of daily living was measured in the oldest old 
subjects with the Groningen Activity Restriction Scale (GARS) which assesses 
nine areas of basic activities of daily living (ADL) and instrumental activities 
of daily living (IADL) respectively [24]. The sum scores for the ADL and IADL 
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range from 9 (competent in all activities) to 36 (unable to perform any activity 
without help) respectively and their sum scores together give the total GARS 
score. Walking time was assessed in the oldest old subjects by a standardized 
six-meter walking test which was validated in previous longitudinal ageing 
studies [25]. Subjects were instructed to walk two laps of three meters each as 
quickly as possible. The time it took for the subjects to walk the total six meters 
was recorded in seconds, using a stop watch. The use of a walking aid was 
allowed during the test. 
8.2.6 Statistical analysis
Data were analyzed separately for men and women. The association between 
IGF-1, IGFBP-3 and handgrip strength was analyzed by linear regression using 
three different models. In model 1, the analysis was adjusted for height, weight 
and age for the middle-aged subjects and height and weight for the oldest old 
subjects. Model 2 and 3 were adjusted for the same covariates as for model 1 
with further adjustments for CRP and comorbidity respectively. In addition, 
the population of middle-aged women was stratified by menopausal state and 
all linear regression analyses were repeated. SPSS 17.0 for Windows was used 
for all analyses. P values < 0.05 were considered statistically significant. 
8.3 Results
8.3.1 Subjects characteristics
Baseline characteristics of the study subjects are presented in Table 1. Mean 
age of the middle-aged subjects was 64.3 years and the age of the oldest old 
subjects was 89 years. Height, weight and handgrip strength were significantly 
higher in men and overall lower in the oldest old subjects. As expected, oldest 
old subjects had a higher number of chronic diseases. IGF-1 and IGFBP-3 levels 
were lower in oldest old subjects compared to the middle-aged subjects (P< 
0.001). For both middle-aged and oldest old subjects, there were no significant 
gender differences in the serum IGF-1 levels, but women had significantly 
higher IGFBP-3 levels compared to men in both studies (P< 0.001). 
Information on menopausal status was available for 325 out of 339 middle-aged 
women. Postmenopausal state, defined as cessation of menstrual period for at 
least one year, was present in 288 (88.6%) of women. Of these, only five (1.5%) 
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women were current users of hormone replacement therapy. Of the 22 (6.8%) 
perimenopausal middle-aged women, there were three (0.9%) current users of 
hormone replacement therapy. 
8.3.4 Serum levels of IGF-1, IGFBP-3 and handgrip strength
The multiple regression models for the association between IGF-1, IGFBP-3 
levels and handgrip strength in the middle-aged and oldest old subjects are 
presented in Table 2 and 3 respectively. Serum levels of IGF-1 were significantly 
associated with higher handgrip strength in the middle-aged women after 
adjusting for age, height and weight (0.11 kg higher handgrip strength per 1 
mmol/L increase in IGF-1 level, P= 0.049). However, significance was lost after 
adjustment for CRP and comorbidity. No significant association was seen 
between handgrip strength and IGF-1 in men and IGFBP-3 in both genders. In 
addition we stratified the group of middle-aged women by menopausal status 
and repeated all linear regression analyses. 
IGF-1 was positively associated with handgrip strength in the postmenopausal 
middle-aged women (0.13 kg higher handgrip strength per 1 mmol/L increase 
in IGF-1, P= 0.037) but not in premenopausal and perimenopausal women. The 
association did not change with adjustment for CRP (0.12 kg higher handgrip 
strength per 1 mmol/L increase in IGF-1, P= 0.040). In postmenopausal middle- 
aged women IGF-1 was positively associated with handgrip strength in the 
fully adjusted model (0.15 kg higher handgrip strength per 1 mmol/L increase 
in IGF-1, P= 0.013), but not in premenopausal and perimenopausal women. 
After exclusion of women receiving hormone replacement therapy these 
associations remained significant in the postmenopausal middle-aged women 
(0.13 kg higher handgrip strength per 1 mmol/L increase in IGF-1, P= 0.037). 
No significant associations were found between IGFBP-3 and handgrip 
strength according to menopausal status (all, P> 0.05). 
Serum IGF-1 levels were significantly associated with higher handgrip strength 
in the oldest old women (0.19 kg higher handgrip strength per 1 mmol/L 
increase in IGF-1 level, P= 0.027) but not in men. After adjustment for CRP 
and comorbidity, the association remained significant (P= 0.023 and P= 0.029, 
respectively). Moreover, serum levels of IGFBP-3 were also significantly 
associated with higher handgrip strength in women only (1.56 kg higher 
handgrip strength per 1 mg/L increase in IGFBP-3 level, P< 0.001). Further 
adjustments did not change this association. 
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Table 2   Serum IGF-1 and IGF1-BP3 levels as determinants of handgrip 
strength in middle-aged-old men and women
Handgrip strength (Kg)
Men (n = 333) Women (n = 339)
β S.E.M. P value β S.E.M. P value
IGF-1 (mmol/l)
  Adjusted for age, height & weight -0.01 0.09 0.929 0.11 0.06 0.049
  Additional adjustment for CRP -0.01 0.09 0.921 0.11 0.06 0.051
  Additional adjustment for comorbiditya -0.08 0.10 0.406 0.08 0.06 0.054
IGFBP-3 (mg/l)
  Adjusted for age, height & weight 0.07 0.45 0.870 0.38 0.33 0.243
  Additional adjustment for CRP 0.06 0.46 0.902 0.36 0.33 0.272
  Additional adjustment for  comorbiditya -0.07 0.49 0.889 0.24 0.34 0.477
Table 3   Serum IGF-1 and IGF1-BP3 levels as determinants of handgrip 
strength in oldest-old men and women
Handgrip strength (Kg)
Men (n = 74) Women (n = 198)
β S.E.M. P value β S.E.M P value
IGF-1 (mmol/l)
  Adjusted for height & weight 0.10 0.19 0.690 0.19 0.08 0.027
  Additional adjustment for CRP  -0.10 0.21 0.661 0.21 0.09 0.023
  Additional adjustment for comorbiditya 0.07 0.20 0.734 0.19 0.09 0.029
IGFBP-3 (mg/l)
  Adjusted for height & weight -0.50 1.00 0.094 1.56 0.37 <0.001
  Additional adjustment for  CRP  0.45 1.01 0.651 1.46 0.40 <0.001
  Additional adjustment for  comorbiditya 0.61 0.99 0.536 1.56 0.37 <0.001
β, estimate
aFor each subject, a sum score of chronic diseases (defined as comorbidity) was assigned. Chronic 
diseases included: diabetes mellitus, chronic obstructive pulmonary disease, malignancy, myocardial 
infarction, stroke and hypertension.
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8.3.5 Serum levels of IGF-1, IGFBP-3 and functional performance and 
ability 
Table 4 shows the multiple regression models for the association between serum 
levels of IGF-1 and IGFBP-3 and activities of daily living and walking time in the 
oldest old subjects. No association was seen between serum levels of IGF-1 and 
activities of daily living in both genders. Serum levels of IGFBP-3 were positively 
associated with the GARS scores in the oldest old women (3.17 points better GARS 
score per 1 mg/L increase in IGFBP-3 level, P= 0.002), but statistical significance 
was not reached in men. An inverse association was seen between serum IGF-1 
levels and walking time in the oldest old men (1.28 seconds longer walking time 
per 1 mmol/L increase in IGF-1 level, P= 0.012). There was no significant association 
between walking time and serum levels of IGFBP-3 in both genders.
8.4 Discussion
We hypothesized that lower levels of anabolic factor IGF-1 are associated with 
lower muscle strength in middle-aged and oldest old subjects. Moreover, we 
hypothesized that lower serum levels of IGF-1 are associated with impaired 
physical performance and disability in the oldest old men and women. Our 
results show that levels of IGF-1 and its binding protein, IGFBP-3 both decrease 
with age and that they are positively associated with muscle strength in post-
menopausal middle-aged and oldest old women, but not in men. Furthermore, 
we found that serum levels of IGF-1 were negatively associated with walking 
speed in oldest old men and IGFBP-3 serum levels were positively associated 
with activities of daily living in oldest old women.
IGF-1 is one of the most important mediators of muscle growth and subsequent 
regeneration [26] affecting muscle performance due to its anabolic, hyper-
trophying signaling effect. IGF-1 is produced mainly in the liver, where its 
synthesis is GH dependent [27], but is also produced in multiple extrahepatic 
tissues acting in an autocrine and paracrine fashion [28]. Besides the age- 
dependent decline in IGF-1 serum levels, tissue responsiveness to IGF-1 [29, 
30] as well as intracellular signaling are less efficient with age [31]. Previous 
studies have shown an association of IGF-1 serum levels in the elderly and 
functional outcome parameters such as muscle strength [10, 32, 33]. 
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In agreement with other studies, we found a decrease in IGF-1 and IGFBP-3 
levels with age, probably as a consequence of the decline in GH synthesis, both 
in male and female subjects [31-33]. However, in contrast to recently published 
studies we found no significant gender differences in IGF-1 levels in the 
middle-aged and oldest old subjects [37, 38]. Gender differences were present 
for IGFBP-3 levels consistent with the findings of previous studies [39]. The 
relation between serum IGF-levels and handgrip strength was present only in 
women. Two other studies concluded that lower values for maximal muscle 
power and optimal shortening velocity were associated with lower circulating 
levels of IGF-1 in women only [32, 40]. More recently, IGF-1 levels were 
associated with exercise capacity in healthy female volunteers [41]. The 
missing positive relation in elderly men in our study might be partly explained 
by the lower IGF-1 levels in men compared to women. A recent study reported 
gender specific reference ranges for different age groups [39]. The serum 
levels of the oldest old male subjects in our study were much lower than 
expected from the reference values (below 25th percentile). A possible 
explanation could be that lower levels of IGF-1 are reflective of increased 
frailty in oldest old men aged 89 years in our study cohort. Another reason for 
the absence of an association in elderly men could be that in men the decline in 
total hormonal burden is associated with detrimental outcome, rather than 
deficiency in a single hormone [42]. Also sex hormones are strongly associated 
with muscle mass in men but not in women [40]. Finally, the missing relation 
between IGF-1 levels and handgrip strength in oldest old men could be 
explained by lack of power due to the limited number of oldest old subjects; 
however this does not explain why in the larger sample of middle-aged men the 
relation is also missing. More research is needed to point out possible 
underlying mechanisms of gender differences in IGF-1 signaling and muscle 
strength.
The age-related decline in GH and IGF-1 serum levels may promote frailty by 
contributing to the loss of muscle mass and strength. A significant positive 
relation has been shown between low plasma IGF-1 and functional outcome, 
such as impaired physical performance and self reported difficulties with 
mobility tasks [10, 32, 33]. However, physical performance has also been found 
to be negatively associated with IGF-1 serum levels [35, 43-46]. Our findings 
regarding functional performance and ADL disability are also conflicting with 
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higher IGF-1 serum levels being associated with slower walking in oldest old 
men and a positive association between serum levels of IGFBP-3 and activities 
of daily living in oldest old women. This last finding is consistent with an 
earlier study that found a potential positive influence of IGF-I and IGFBP3 in 
women with regard to walking speed and disability [10]. Others have reported 
on the association between walking speed and IGF-1 serum levels in 349 oldest 
old subjects and found an association between IGF-1 levels and walking speed 
only in 54 subjects with a Body Mass Index above 30 [9]. The finding that IGF-1 
levels are negatively associated with walking speed in oldest old men is coun-
terintuitive and is not supported by a limited number of earlier studies [9, 10]. 
A chance finding due to the limited size of oldest old men in this study cannot 
be excluded. 
Despite of these conflicting results which could be explained by study 
population homogeneity with subsequent smaller ranges of IGF-1 levels, the 
potential influence of GH/IGF-1 on muscle function can best be illustrated by 
administration of these hormones. Acute administration of GH regulates 
muscle mitochondrial function by increasing the levels of several key 
mitochondrial proteins switching fuel utilization toward fat oxidation [47]. In 
addition, exogenous systemic administration of IGF-1 increases the rate of 
skeletal muscle functional recovery after injury [48], improves contractile 
function [49, 50] and fatigue resistance and induces an increase in muscle 
oxidative enzymes [48]. 
Our study has several strong points, particularly the large size of the study 
population, the large age range and its external validity, i.e. the included 
subjects representing the general population. The number of included oldest 
old subjects of our study is significantly higher compared to other studies. 
Therefore we conclude that our study is very comprehensive with a large 
number of subjects (n= 944, age range (38-89 years) and the largest number of 
oldest old subjects (n= 272, all aged 89 years). Furthermore handgrip strength 
is a reliable tool to measure overall muscle strength [21-23]. However, the 
present study was set up in a cross-sectional way and IGF-1 and IGFBP-3 were 
only measured at one time point in both study cohorts. Future longitudinal 
analysis in our middle-aged cohort will allow for further insight into the 
association of growth hormone and muscle strength as well as functional 
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performance and ability. We were unable to measure body composition, 
because the oldest old subjects were visited at their home. Furthermore, we 
did not control for additional factors that could potentially influence the 
associations between the somatotropic axis and muscle strength, such as sex 
hormones, which were not available due to sample limitations. Finally, the 
relation between serum and muscle IGF-1 is not necessarily strong, because of 
different isoforms in muscle and liver [51,52] and we were not able to assess 
muscle IGF-1 directly. Also, we have not measured IGF-1 bioactivity [53] as a 
possibly more accurate measure of IGF-1 biological activity. 
In summary, we found an association between serum IGF-1 levels and handgrip 
strength in middle-aged postmenopausal and oldest old women, but not in 
men. Maintenance of higher IGF-1 levels could therefore contribute to 
preservation of muscle function and subsequent muscle performance in an 
elderly female population. Further research is needed to address gender 
differences in IGF-1 signaling in muscle in oldest old subjects.
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High innate production capacity 
of Tumor Necrosis Factor-α and decline 
of handgrip strength in old age
Taekema DG, Westendorp RGJ, Frölich M, Gussekloo J




Increased signaling of the pro-inflammatory cytokine Tumor Necrosis Factor-α 
(TNF-α) elicits apoptosis of skeletal muscle cells in various animal models. 
Within a population-based prospective follow up study of elderly people aged 
85 years we show that a high innate production capacity of TNF-α precedes a 
steeper decline in muscle strength over time. 
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9.2 Introduction
Muscle weakness, sarcopenia, is a common cause of disability in elderly people 
and associates with an increased mortality risk [1-6]. Because muscle 
weakness and systemic inflammation often co-occur in old age, it has been 
questioned whether this co-occurrence indicates a causal mechanism [7-13]. 
The underlying mechanisms that could explain for this association have not 
been fully resolved yet. 
Recent data from experimental rat models show that the pro-inflammatory 
and catabolic cytokine TNF-α contributes to skeletal muscle loss [14, 15]. In 
old rats, it has been shown that increased intracellular TNF-α signaling leads 
to apoptosis of muscle cells via the intracellular Fas-associated death signaling 
pathway, predominantly in type IIa and IIb fast fibers [14, 16]. Moreover, in 
rats the age associated increase in TNF-α signaling was completely abrogated 
by caloric restriction, in line with the attenuation of TNF-α levels in human 
skeletal muscle upon resistance exercise [17]. 
To study whether a systemic inflammation or merely a high innate production 
capacity of TNF-α contributes to decline of muscle strength in elderly people, 
we studied the relation between the ex-vivo production capacity of pro- and 
anti-inflammatory cytokines and changes in handgrip strength within a 
prospective population-based follow-up study of elderly people aged 85 years 
and over.
9.3 Methods
The Leiden 85-plus Study is a population-based, prospective follow-up study of 
inhabitants of the city of Leiden, the Netherlands. All inhabitants who turned 
85 years between 1997 and 1999 were invited to participate. In total 599 
persons aged 85 years participated, i.e. 87% of all eligible inhabitants. For 
further details we refer to previous publications [18, 19]. The Medical Ethical 
Committee of the Leiden University Medical Center approved the study and all 




Handgrip strength was assessed at age 85 years (baseline) and after four years 
of follow-up at 89 years. Handgrip strength was measured in kilograms (kg) 
with a Jamar hand dynamometer (Sammons Preston Inc, Bolingbrook, IL). One 
test trial was allowed. Thereafter, three trials followed and the maximal score 
was taken for analysis. 
9.3.2 Characteristics of participants 
Baseline data on the presence of chronic somatic diseases were obtained from 
the general practitioner, pharmacist’s records, and inferred from the electro-
cardiogram (ECG) and blood sample analysis. Presence of somatic diseases 
included cardiovascular disease, diabetes mellitus, chronic obstructive 
pulmonary disease, malignancy, arthritis (including osteo-arthrosis and 
polymyalgia rheumatica) and Parkinson’s disease. Co-morbidity was defined 
as the total number of somatic diseases per participant. Height (m) and weight 
(kg) were measured at baseline.
9.3.3 Systemic inflammation and cytokine production capacity
Systemic inflammation was estimated by circulating levels (mg/L) of C-reactive 
protein (CRP). CRP was measured with a standard, fully automated P800 
Modular system (Roche, Boehringer Mannheim, Germany) with a sensitivity of 
1 mg/L. 
We hypothesized that TNF-α was the cytokine associated with decline in 
handgrip strength. However, the innate immune system signals by other key 
cytokines also. Therefore, we also analyzed the associations with the pro-in-
flammatory cytokines Interleukin-1-beta (IL-1β) and Interleukin- 6 (IL-6) and 
natural occurring antagonistic, anti-inflammatory cytokines Interleukin-10 
(IL-10) and Interleukin-1 RA (IL-1 RA). 
The production capacity of cytokines (pg/mL) was assessed by measuring the 
cytokine production capacity of whole blood samples upon ex vivo stimulation 
with lipopolysaccharide (LPS) as described elsewhere [20]. In short, cytokine 
production peak levels were assessed with an ex-vivo whole-blood assay. All 
venous blood samples were drawn in the morning before 11.00 Am to exclude 
circadian variation. The blood was collected in heparinised tubes and samples 
were diluted 2-fold with RPMI-1640 (Sigma, St. Louis, MO) and stored after 
addition of 10 pg/ml E. coli-derived LPS (Difco Laboratories, Detroit) at 37˚C 
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and 5% CO2. After centrifugation, the supernatants were stored at -80 °C until 
assayed for TNF-α in the 4-hour samples and IL-10, IL-1β, IL-1RA, IL-6 in the 
24-hour samples using standard ELISA techniques (Central Laboratory of the 
Blood Transfusion Service, Amsterdam, The Netherlands). The inter-assay 
cubic variance (Cv) for the cytokine assays, influenced also by dilutions for 
high stimulated values, are below 6 % for IL-1β and IL-10; below 8 % for TNF-α 
and IL-6; whereas IL-1 RA ranged up to 12 %. Intra-assay CV was 0.5 to 1 % 
below inter-assay CV.
9.3.3 Data analysis
Differences in distribution of various parameters between participants were 
compared with parametric tests (ANOVA, paired t-test) or non-parametric 
tests (Mann-Whitney U) depending on the distribution of the data. 
For the cross-sectional analysis we used the linear regression model: 
handgrip strength 85 (kg) = C + ß1*determinant + ß2*gender + ß3*height+ 
ß4*weight.
For the prospective analysis, we used the linear regression model: decline 
handgrip strength (89-85 in kg) = C + ß1*determinant + ß2*gender + ß3*height 
+ ß4* weight + ß5*((handgrip strength 85 + handgrip strength 89)/2)) [21]. 
Due to the skewness of the data log transformation was performed for this 
analyses.
To circumvent potential confounding by systemic inflammation we restricted 
the study group to those participants who were without signs of low-grade 
systemic inflammation at baseline defined as CRP levels < 4 mg/L and 
unstimulated TNF-α production < 100 pg/ml. 
The cut off point for CRP was chosen because the median plasma level of CRP 
was 3 mg/L in the whole study sample (table 1). We considered participants 
with a CRP level below 3 mg/L to be without low-grade systemic inflammation. 
The cut off point for TNF-α was chosen because an unstimulated production 
above 100 pg/ml is in all likelihood the result of agitation of the samples or 
systemic inflammation due to underlying somatic diseases and therefore these 
samples were excluded from the analysis [20]. 





At baseline, handgrip strength was measured for 555 participants, that is 92.7 
% of the total of 599 participants of the Leiden 85-plus Study. Figure 1 shows 
the flow of participants and the reasons for not completing follow-up. Table 1 
presents the baseline characteristics of the participants (n = 555) depending 
on completion of follow-up. Some 194 (35%) were male. Mean handgrip 
strength at 85 years was 22.9 ± 8.9 kg (mean ± SD) and did not differ between 
participants who completed and did not complete follow-up. Height and weight 
were comparable. The number of co-morbid conditions and CRP was higher in 
participants who did not complete follow-up (P≤ 0.003). In the unstimulated 
samples production of IL-1RA was elevated in participants who did not 
complete follow up (P= 0.02). After LPS stimulation cytokine production 
capacity of IL-1β and IL- 6 was higher in participants who completed follow-up 
(P≤ 0.03). 
At age 89 years, 358 (64.5%) participants were alive. Some 89 (29.3%) were 
male. 
Mortality among men was significantly higher than in women (P= 0.008). 
Handgrip strength was re-assessed in 307 participants at age 89 years and 
had declined significantly by 4.2 ± 4.7 kg (mean ± SD, P< 0.001) after four years 
of follow up. 
At baseline CRP plasma levels (0.29 kg lower per doubling of CRP plasma level, 
P= 0.001) and co-morbidity (0.50 kg lower per number of co-morbid disease, 
P= 0.02) were correlated with handgrip strength. During follow-up no association 
was found between baseline CRP plasma levels or co-morbidity and decline in 
handgrip strength (P> 0.48). 
As co-morbid conditions may explain both markers of systemic inflammation 
and low handgrip strength, we restricted the analyses to participants who at 
baseline were without signs of low-grade systemic inflammation, defined as 
CRP levels < 4 mg/L and unstimulated TNF-α production < 100 pg/ml (see 
methods). From the 260 participants without signs of low-grade systemic 
inflammation at baseline, 162 completed the follow-up (see figure 2).
Table 2 presents the association between the production capacity of pro- and 
anti-inflammatory cytokines and handgrip strength in participants without 
signs of low-grade systemic inflammation at baseline.
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At baseline, no association was found between cytokine production capacity 
and handgrip strength. However, in the prospective analyses a higher production 
capacity of TNF-α was associated with a steeper decline in handgrip strength 
over time (Table 2, 1.3 kg faster decline per doubling of TNF-α production, P= 
0.03). When CRP and co-morbidity were added to the model this did not change 
the results. LPS stimulated production levels of TNF-α, IL-6, and IL-1 were in 
this study significantly correlated (linear regression, P<0. 001). When we 
analysed the association between TNF-α production capacity and decline in 
handgrip strength with adjustment for the production capacities of all 
cytokines, the association between TNF-α production capacity and decline in 
handgrip strength became even stronger (2.7 kg faster decline per doubling of 
TNF-α production, P= 0.02).
Figure 1   Flow of participants
599 participants Leiden 85 plus
555 participants aged 85 years 
358 participants alive at 89 years
44 non-completed handgrip strength tests
Refused participation n = 3
Physically impaired n =17
Cognitive impaired n = 9
Did not follow instructions n = 5
Other reasons, 
e.g. technical dif�iculties n =10
n=197 died during follow up
307 participants with handgrip 
strength test at follow up
51 non-completed handgrip strength tests
Refused participation n = 1
Physically impaired n = 7
Cognitive impaired n = 9  
Withdrew from study n = 32
Other reasons, 
e.g. technical dif�iculties n = 2
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Figure 2   Flow of participants in sample without low-grade systemic 
inflammation
599 participants Leiden 85 plus
555 participants aged 85 years 
260 participants in restricted 
sample
44 non-completed handgrip strength tests
Refused participation n = 3
Physically impaired n =17
Cognitive impaired n = 9
Did not follow instructions n = 5
Other reasons, 
e.g. technical dif�iculties n =10
295 excluded with CRP levels above 4 mg/L 
and unstimulated TNF-α production above 
100 pg/ml
162 participants with handgrip 
strength test at follow up
Died n = 77
21 Non-completed handgrip strength tests 
Refused participation n = 1
Physically impaired n = 2
Cognitive impaired n = 5
Withdrew from study n = 10
Other reasons, 
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9.5 Discussion
In this population-based prospective follow up study of elderly people aged 85 
years we showed that not the actual inflammatory state, but a high production 
capacity of pro-inflammatory cytokine TNF- α precedes a greater decline of 
handgrip strength in old age. 
The association with production capacity of TNF- α was not changed by 
adjustments for production capacity of the other cytokines, thus supporting 
the hypothesis that TNF- α signaling contributes to muscle weakness in elderly 
people.
Earlier, several cross-sectional human studies have shown correlations between 
muscle strength, muscle mass, and circulating levels of CRP, IL-6, and TNF-α 
[6-8, 12]. Moreover, few prospective studies found that high circulating levels 
of IL-6 and TNF-α predicted the decline in fat free mass as an estimate of 
muscle mass [9, 10]. These prospective data may reflect a causal relationship 
between systemic inflammation and muscle weakness but it is just as likely 
that these inflammatory markers are a reflection of co-morbid disease, or late 
consequences of muscle weakness and or inactivity. The alternative interpretation 
is that some of these inflammatory markers specifically contribute to the loss 
of skeletal muscle and or muscle strength. 
Here we show that a high innate production capacity of TNF-α precedes muscle 
weakness in elderly people. To our knowledge we are the first to show that a 
high innate production capacity of TNF-α is a risk factor for decline of muscle 
strength in men. This relation is biologically not unexpected. TNF-α, first 
denoted as ‘cachectin’ [22], has various pleiotropic actions among which there 
are inflammation and apoptosis. Administration of TNF-α in rodent models 
results in muscle atrophy [22], and the rat models show specific associations 
with apoptosis in type II fiber muscle cells [14-16]. Moreover, anti-TNF-α 
therapy protects dystrophic skeletal muscle from necrosis in a mice model of 
Duchenne’s myopathy [23]. 
The potential mechanisms how TNF-α leads to decline of muscle strength are 
several and not yet elucidated. TNF-α has systemic effects by decreasing 
circulating levels of insulin like growth factor and growth hormone contributing 
to muscle weakness [24, 25]. Furthermore, specific up-regulation of TNF-α 
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expression led to an increase in intracellular Fas-associated death domain 
(FADD) protein, an increase in DNA fragmentation and is thus strongly 
suggestive that TNF-α mediated apoptosis causally relates to the age associated 
atrophy in rats [14, 16]. Noteworthy, these phenomena were observed in the 
muscles that predominantly consist of type II fibers, whereas the muscles that 
predominantly consist of type I fibers do not show a TNF-α mediated cell loss. 
The reason why only type II muscle fibers are affected is unknown.
In elderly people, the association between markers of systemic inflammation 
and muscle weakness is difficult to interpret because of potential confounding 
by co-morbid disease. We have circumvented these confounders by using two 
strategies. First, we restricted the sample to 260 participants without signs of 
low-grade systemic inflammation at baseline as determined by low circulating 
levels of CRP and unstimulated production of TNF-α. Second, we assessed the 
production capacity of pro-inflammatory cytokines after LPS challenge which 
has been shown to be under tight genetic control; up to 80% of the variation in 
cytokine production in the ex-vivo assay is explained by heritable factors and 
is likely to mirror the in-vivo host response [26] An association between innate 
cytokine production capacity and development of poor handgrip strength over 
time could therefore be interpreted as an argument in favor of a causal relation. 
The study has several additional strengths. The Leiden 85-plus Study is a 
prospective population-based cohort study with extensive measurements for 
health and functioning with an almost complete follow up. Furthermore, the 
longitudinal design allowed us to study causal relations of muscle strength in 
the oldest old. A possible weakness of this study is that the restriction prohibits 
generalisibility of the results to the general population of the oldest old. 
However, the aim of this study was to provide insight into the pathogenesis of 
declining handgrip strength depending on inflammatory characteristics. 
In conclusion, within a population-based prospective follow up study of elderly 
people aged 85 years we showed that a high innate production capacity of 
TNF-α precedes a steeper decline in muscle strength over time. We consider it 
likely that a high innate production capacity of TNF-α contributes to declining 
muscle strength in old age. 
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The aim of the research presented in this thesis was to study candidate 
determinants of muscular and functional vitality during ageing. The first part 
of this thesis focused on the functional phenotype with an emphasis on 
handgrip strength, gait speed and functional abilities. In the second part of the 
thesis the focus was on possible determinants of muscle weakness in oldest old 
people. The underlying motivation for this research was to gain insight into 
possible causes and consequences of ageing muscle and functional decline 
with the objective to enable elderly people to age more successfully in future 
by prevention or treatment of possible causes. 
10.2  Muscle weakness, functional disability and 
mortality
Declining muscle mass and muscle strength, referred to as sarcopenia and 
dynapenia, are prevalent features in very old people. Some report prevalences 
of sarcopenia as high as 60% in the general oldest old population [1]. Since 
demography changes dramatically, by 2050, oldest old people will account for 
one-fifth of all older persons globally; one can presume that sarcopenia and 
dynapenia will become common health problems in due course [2]. Hence, 
muscle strength has an important impact on general health of elderly people. 
Muscle weakness is associated with declining physical fitness, increased 
disability, cognitive decline and mortality [3-18]. Functional measurements, 
such as gait speed, predict functional limitations of the lower body, cognitive 
decline and survival in older people. [13, 19-22]
All these associations raise the question about the value of muscle strength 
and functional tests as gait speed as markers or predictors of adverse health 
outcomes in oldest old people. Such a test could be a useful part of the clinical 
evaluation of very old patients in determining which patients are most at risk 
of accelerated decline in the near future and who could still benefit from 
interventions. Furthermore, knowledge about survival might benefit patient’s 
wellbeing and quality of life because it could improve clinical decision making 




10.3.1 Leiden 85-plus Study 
The main body of the research presented in this thesis is part of the Leiden 
85-plus Study. The Leiden 85-plus Study is a community-based prospective 
follow-up study of inhabitants of the city of Leiden, the Netherlands. Enrolment 
took place between 1997 and 1999. All inhabitants, including nursing home 
residents, who reached the age of 85 years, were eligible to participate. There 
were no selection criteria on health or demographic characteristics [23]. In 
total 599 persons participated, 87% of all eligible inhabitants. At baseline, a 
research nurse visited participants at their place of residence. During these 
visits, face-to-face interviews, and performance tests were conducted. Also a 
blood sample was taken and the electrocardiogram was recorded. Follow up 
visits were performed annually for a period of five years and follow up on 
survival still continues. All subjects were followed up for survival until January 
2010 with a follow-up period of 12.2 years. Dates of deaths were obtained from 
the Dutch civic registry. 
10.3.2 Leiden Longevity Study 
For purposes of comparison with the oldest old population, the middle aged 
participants of the Leiden Longevity Study are included in two studies 
presented in this thesis. In the Leiden Longevity Study, 420 families were 
recruited consisting of long-lived Caucasian siblings together with their 
middle aged offspring and the partners thereof [24]. There were no other 
inclusion criteria for the offspring, other than being offspring of the 
nonagenarian siblings or being the partner of the offspring. Our studies 
included the cross-sectional baseline sample of the middle aged offspring and 
their partners (n= 670). All participants visited the study center where all 




10.4  Functional phenotype as predictor of health 
and survival
10.4.1 Handgrip strength as a predictor of health and survival
The aim of the studies described in chapters 2 and 3 was to study the predictive 
properties of handgrip strength with regard to functional, psychological and 
social health domains and survival. Handgrip strength was used as a proxy for 
muscle strength. The findings showed that low handgrip strength was a 
predictor of accelerated dependency in activities of daily living and also 
predicted accelerated cognitive decline. Based on these results it was 
concluded that measuring handgrip strength could be a useful instrument in 
geriatric clinical practice to identify those oldest old patients at risk for 
accelerated decline in these domains. The importance of handgrip strength 
measurement as a screening tool was further emphasized by the finding that 
lower handgrip strength and a steeper decline in handgrip strength over time 
were both associated with a twofold increased mortality risk and could 
therefore serve as a means for prognostication in very old patients. However 
more studies are needed into this matter in other populations, such as patients 
admitted to clinical wards and outpatient clinics. 
10.4.2 Gait speed, functional ability and survival
The study of the association between gait speed and survival in a population of 
oldest old participants is described in chapter 4. This study showed that gait 
speed was associated with survival in oldest old people aged 85 years with a 
follow up of 12 years. However, the predictive value of gait speed in very old 
people was weakened by cognitive decline, depressive symptoms, disability in 
instrumental activities of daily living (IADL), and sedentary life style, all 
common features in geriatric practice. Inability to perform a walking test was 
highly discriminative of poor survival. Furthermore, IADL disability was 
associated with a higher predictive value for poor survival in oldest old people 
compared to gait speed, independent of common confounders and gait speed. 
With regard to prognostication in very old individuals the value of gait speed 
should be reconsidered. In those unable to walk, simple IADL assessment by 
questionnaire which is already part of the comprehensive geriatric assessment 
is possibly a better predictor than handgrip strength and gait speed with 
regard to survival. 
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10.4.3 Functional disability and depressive symptoms over time
In chapter 5 the results of the study of the longitudinal associations of 
depression and depressive symptoms with cognition, chronic diseases and 
functional ability in oldest old people are presented. The findings of this study 
suggest that current functional ability at age 85 years in personal (ADL) and 
instrumental activities (IADL) of daily living is primarily associated with 
depressive symptoms in oldest old people. Over time IADL disability was 
associated with an increase in depressive symptoms at age 90 years. Moreover, 
increasing ADL and IADL disability during follow up was associated with an 
increase in depressive symptoms at age 90 years. This association was 
independent of cognitive functioning for people with mild dementia or normal 
cognitive functioning, and comorbidity. Surprisingly, depressive symptoms at 
85 years were not associated with increased functional disability in oldest old 
people. These are strong reasons to detect and intervene with older people 
with declining functional ability as a possible means to prevent depressive 
symptoms during ageing. Further clinical studies should determine whether 
rehabilitation therapy could contribute to improvement in depressive symptoms.
10.4.4  The temporal relationship between cognitive performance and 
muscle weakness
Cognitive decline and muscle weakness are prevalent health conditions in 
elderly and often co-occur in elderly persons. The temporal relationship 
between decline of muscle strength and cognitive performance is still unclear. 
Does poor handgrip strength precede and therefore mark cognitive decline or 
is the opposite the case. In the study into this relationship described in chapter 
6 better cognitive performance was associated with better muscle strength 
and a slower decline in muscle strength. In the longitudinal analysis better 
baseline cognitive performance, in particular attention, processing speed and 
memory function was associated with slower decline in handgrip strength, 
whereas low baseline handgrip strength was not associated with an accelerated 
decline in cognitive performance. This suggests that cognitive decline precedes 
muscle weakness. Cognitive decline in elderly subjects should make clinicians 
vigilant for muscle weakness in the near future. Further clinical research is 




10.5  Candidate determinants of muscle weakness in 
oldest old people
10.5.1 The association between blood pressure and muscle strength
In chapter 7 the longitudinal association between blood pressure and handgrip 
strength is presented. This association was studied in oldest old people (Leiden 
85-plus Study) and middle aged people (Leiden Longevity Study). Results 
showed a positive association between systolic, diastolic and pulse pressure and 
handgrip strength in oldest old people. In addition, declining systolic, diastolic 
and pulse pressure were associated with a decline in handgrip strength during 
follow up. Blood pressure was not associated with handgrip strength in the 
middle aged people. A possible hypothesis explaining this counterintuitive 
finding of a higher blood pressure being beneficial is described. In short, ageing 
is associated with increased peripheral vascular resistance and a reduction in 
vasodilation capacity. Increased vascular resistance during the ageing process 
requires higher pressure as a mechanism to maintain tissue perfusion as a 
means to prevent further ischemic end organ damage in kidney, brain and 
skeletal muscle. It is clear from these findings that further research is needed 
into the implications of hypertension and antihypertensive treatment in the 
general population of oldest old and whether the improvement on cardiovascular 
endpoints comes at a cost of muscle weakness in this population.
10.5.2  Insulin like Growth Factor-1 and muscle strength in middle 
aged and oldest old 
The assessment of the association between Insulin-like Growth Factor-1 
(IGF-1), IGF binding protein 3 (IGFBP-3) and functional outcome in middle-aged 
and oldest old people is described in chapter 8. The results show that levels of 
IGF-1 and its binding protein, IGFBP-3 both decrease with age and that they are 
positively associated with muscle strength in postmenopausal middle-aged 
and oldest old women, but not in men. Furthermore, we found that serum levels 
of IGF-1 were negatively associated with walking speed in oldest old men and 
IGFBP-3 serum levels were positively associated with activities of daily living 
in oldest old women. However, further research is needed to explain the found 
gender differences in IGF-1 signaling in muscle in oldest old subjects. The 
age-related decline in GH and IGF-1 serum levels may promote frailty by 
contributing to the loss of muscle mass and strength. Maintenance of higher 
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IGF-1 levels could therefore contribute to preservation of muscle function and 
subsequent muscle performance in an elderly female population. 
10.5.3 Innate cytokine production capacity and muscle weakness 
To study whether a systemic inflammation or merely a high innate production 
capacity of TNF-α contributes to decline of muscle strength in elderly people, 
we studied the relation between the ex-vivo production capacity of pro- and 
anti-inflammatory cytokines and changes in handgrip strength within a 
prospective population-based follow-up study of elderly people aged 85 years 
and over in chapter 9. We showed that it is not the actual inflammatory state, 
but a high production capacity of pro-inflammatory cytokine TNF- α that 
precedes a greater decline of handgrip strength in old age. The association 
with production capacity of TNF- α was not changed by adjustments for 
production capacity of the other cytokines, thus supporting the hypothesis 
that TNF- α signaling contributes to muscle weakness in elderly people. The 
association between innate cytokine production capacity and development of 
poor handgrip strength over time could be interpreted as an argument in favor 
of a causal relation. This relation is biologically not unexpected. TNF-α, first 
denoted as ‘cachectin’ has various pleiotropic actions among which there are 
inflammation and apoptosis.
10.6 Conclusion and future perspectives
In a population based cohort of oldest old people the functional phenotype was 
a strong predictor of survival and future functional ability. The results of the 
studies presented in this thesis allow us to speculate about the predictive 
value of functional measurements as markers of vitality in a clinical population 
of oldest old patients. Use of these markers of vitality could contribute to 
increased vigilance in clinicians for increased risk of health problems in their 
very old patients, such as depressive symptoms, cognitive decline, disability in 
activities of daily living and mortality. Furthermore, these vitality markers 
could be helpful in individual prognostication and decision making in very old 
patients who are faced with serious illnesses. However, the value of handgrip 
strength, gait speed and ability in instrumental activities of daily living now 




With regard to candidate determinants of muscle weakness in oldest old 
people the finding that higher blood pressure is associated with better muscle 
strength over time is interesting. First, it contributes to the finding of others 
[25,26] that higher blood pressure in elderly seems overall beneficial and not 
necessarily harmful in oldest old persons with regard to muscle strength. 
Second, it encourages us to reevaluate current guidelines on hypertension 
treatment in aging populations, thus promoting further clinical research into 
the association between blood pressure and healthy aging in very old people.
TNF-α innate production capacity is another strong determinant of future 
muscle weakness independent of comorbidity or production capacity of other 
cytokines. This is of interest because the innate production capacity is largely 
a hereditary trait [27]. Further research needs to be done to confirm these 
results in other populations of elderly people. If so, anti TNF-α therapy could 
possibly be a means to prevent or treat sarcopenia in elderly at risk. 
In women aged 90 years, muscle strength is associated with higher levels of 
IGF-1, but not in men. It is of interest to study the longitudinal association 
between IGF-1, the binding protein IGFBP3 and muscle strength in ageing men 
and women. This results hints at a gender difference in IGF-1 signaling with 
regard to muscle tissue. And yet again, further research needs to be done to 
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Tijdens de veroudering verandert het lichaam. Een algemeen kenmerk van deze 
veroudering is het verlies van krachten, niet alleen in figuurlijke zin, maar ook 
letterlijk als het verlies van spierkracht. Met dit verlies van spierkracht komt 
vaak ook functieverlies. Vanzelfsprekende handelingen, zoals lopen, wassen en 
aankleden worden lastiger voor de ouder wordende mens. En uiteindelijk kan 
spierzwakte ook leiden tot een situatie waarin men op oudere leeftijd afhankelijk 
wordt van de zorg van anderen of gedwongen is te verhuizen naar een andere 
woonomgeving. Het is daarom belangrijk om onderzoek te verrichten naar 
factoren die vitaliteit van spieren en functioneren bevorderen. Het eerste deel 
van dit proefschrift richt zich op onderzoek van het functionele fenotype, zoals 
knijpkracht, loopsnelheid en de dagelijkse levensverrichtingen. Het tweede deel 
van dit proefschrift richt zich op mogelijke determinanten van spierzwakte bij 
ouderen. Een belangrijke motivatie van dit onderzoek was inzicht te verkrijgen 
in mogelijke oorzaken en gevolgen van veroudering van spieren en functionele 
achteruitgang bij oudere mensen. Het uiteindelijke doel was om mogelijk 
beïnvloedbare factoren te identificeren die kunnen bijdragen aan een succesvolle 
veroudering van mensen. 
11.2  Spierzwakte, functionele achteruitgang en 
mortaliteit
De afname van spiermassa en spierzwakte, ook genoemd sarcopenie en dynapenie, 
komt veel voor bij zeer oude mensen. De gerapporteerde prevalentie is variabel, 
maar wordt geschat op ongeveer 60% in de algemene populatie van oudste oudere 
mensen [1]. 
In de komende jaren zal de demografie dramatisch gaan veranderen en in 2050 zal 
een vijfde deel van de wereldbevolking ouder zijn dan 85 jaar[2]. Gezien de 
toename van het aantal zeer oude mensen is te verwachten dat sarcopenie en 
dynapenie veelvoorkomende gezondheidsproblemen zullen zijn. Spierzwakte en 
achteruitgang in functionele prestaties, zoals bijvoorbeeld loopsnelheid zijn 
geassocieerd met achteruitgang van de algehele gezondheid van ouderen. In 
studies zijn beide geassocieerd met afname van vitaliteit, functionele achteruitgang 
in dagelijkse levensverrichtingen, cognitieve stoornissen en mortaliteit [3-22]. 
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De belangrijkste vraag is nu of spierkracht en functionele meetinstrumenten 
bruikbaar zijn in de kliniek als markers of voorspellers van toekomstige 
achter uitgang van de gezondheid van oudere mensen. Een functioneel meet-
instrument in de klinische setting, zoals loopsnelheid of knijpkracht, zou het 
dan voor artsen mogelijk maken om bij oude mensen te voorspellen wie een 
groot risico heeft op achteruitgang van gezondheid en functioneren in de 
nabije toekomst. Ook kennis over overleving zou van waarde kunnen zijn bij de 
klinische besluitvorming bij ernstige aandoeningen. Immers, bij een beperkte 
overleving ten gevolge van ernstige spierzwakte of matig functioneren zal 
worden afgezien van een zeer belastende behandeling van een andere aan - 
doening. Dit kan bijdragen aan welzijn en kwaliteit van leven van oudste oudere 
patiënten.
11.3 Studie populaties
10.3.1 Leiden 85-plus Studie 
Een belangrijk deel van het onderzoek beschreven in dit proefschrift maakt 
deel uit van de Leiden 85-plus Studie. De Leiden 85-plus Studie is een 
longitudinaal bevolkingsonderzoek van een cohort Leidse ouderen van 85 jaar 
oud. Werving voor deze studie vond plaats tussen 1997 en 1999. Alle inwoners 
van Leiden, ook als zij woonachtig waren in een verpleeghuis, werden kort na 
hun 85e verjaardag uitgenodigd om deel te nemen aan het onderzoek. Er werd 
niet geselecteerd op gezondheid of demografische kenmerken [23]. In totaal 
hebben 599 persons deelgenomen aan de studie, dat is 87% van alle potentiële 
deelnemers. Na inclusie in de studie werden de deelnemers thuis bezocht door 
een onderzoeksverpleegkundige. Tijdens deze bezoeken werd de deelnemer 
geïnterviewd en ook werden meerdere meetinstrumenten afgenomen. Tenslotte 
werd nog bloed afgenomen voor onderzoek en een electrocardiogram verricht. 
Gedurende 5 jaar werden vervolgens alle nog in leven zijnde deelnemers 
eenmaal per jaar bezocht. 
11.3.2 Leiden Langleven Studie 
Ter vergelijking van de resultaten van het onderzoek bij oudste oudere deel - 
nemers werden ook de deelnemers van middelbare leeftijd van de Leiden 
Langleven Studie geïncludeerd in twee onderzoeken. In de Leiden Langleven 




broers en zussen samen met de kinderen en de partners van hun kinderen [24]. 
In de twee voornoemde onderzoeken werd de cross-sectionele data die verzameld 
was bij de inclusie gebruikt van de kinderen en hun partners (n= 670). De deel- 
nemers van deze studie bezochten het studiecentrum in Leiden. 
11.4  Functionele fenotype als predictor van 
gezondheid en overleving
11.4.1 Handknijpkracht als voorspeller van gezondheid en overleving
De studies beschreven in hoofdstuk 2 en 3 hadden beide tot doel de voor -
spellende waarde van handknijpkracht te onderzoeken. Handknijpkracht is 
een goede maat voor algehele spierkracht. Allereerst werd onderzocht wat de 
relatie was tussen handknijpkracht en functionele, psychologische en sociale 
gezondheidsdomeinen (hoofdstuk 2). De resultaten toonden aan dat een slechte 
handknijpkracht een versnelde achteruitgang voorspelde van het functioneren 
in de dagelijkse levensverrichtingen, zoals eten, drinken en toiletgang, alsmede 
een versnelde achteruitgang van het cognitieve functioneren. Op basis van 
deze resultaten werd geconcludeerd dat handknijpkracht mogelijk gebruikt 
zou kunnen worden in de kliniek om die oude mensen te identificeren die een 
verhoogd risico hebben op achteruitgang in het functionele en psychologische 
domein in de nabije toekomst. Het mogelijk belang van handknijpkracht als 
screeningsinstrument werd bevestigd door de bevinding dat een slechte hand-
knijpkracht geassocieerd was met een tweemaal hoger risico op overlijden. 
Verder bleek niet alleen de absolute handknijpkracht van belang, maar was 
ook de achteruitgang van de handknijpkracht geassocieerd met een eveneens 
tweemaal verhoogd risico op overlijden. Handknijpkracht kan daarom mogelijk 
ook een rol spelen bij voorspellingen over de prognose van een individu. Echter 
hiervoor zijn nog veel meer studies nodig, ook in klinische populaties. 
11.4.2 Loopsnelheid, dagelijkse levensverrichtingen en overleving
De studie naar de associatie tussen loopsnelheid en overleving in een populatie 
oudste oudere deelnemers wordt beschreven in hoofdstuk 4. De uitkomsten 
van dit onderzoek toonden dat een langzame loopsnelheid was geassocieerd 
met een slechtere overleving bij deelnemers van 85 jaar oud tijdens een 
vervolgperiode van ruim 12 jaar. Echter, opvallend was de bevinding dat de 
voorspellende waarde van loopsnelheid sterk werd beïnvloed door cognitieve 
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stoornissen, depressieve symptomen, beperkingen in de instrumentele dagelijkse 
levensverrichtingen (IADL) en verminderd activiteitenpatroon van de deel- 
nemers. Al deze factoren zijn frequent aanwezig bij de groep van oudste 
ouderen. Ook bleek dat het niet kunnen verrichten van de looptest geassocieerd 
wat met een significant hogere sterfte. Aanvullende analyses toonden aan dat 
beperkingen in de IADL, meer nog dan loopsnelheid, geassocieerd waren met 
een sterker verhoogd risico op overlijden, zelfs nadat gecorrigeerd was voor 
mogelijke beïnvloedende factoren. Bij zeer oude mensen die niet meer kunnen 
lopen is een evaluatie van de IADL vaardigheden door middel van een vragen- 
lijst mogelijk een betere voorspeller van overleving dan een looptest. 
11.4.3  De associatie tussen functionele achteruitgang en depressieve 
symptomen 
In hoofdstuk 5 worden de resultaten gepresenteerd van de studie naar de 
longitudinale relatie van depressieve symptomen met cognitie, chronische 
ziekte en functionele achteruitgang. De resultaten van deze studie tonen dat 
huidig functioneren op 85 jarige leeftijd in algemene dagelijkse levensverrich-
tingen (ADL) en instrumentele dagelijkse levensverrichtingen (IADL) met name 
geassocieerd was met depressieve symptomen bij oudste oudere deelnemers. 
In de longitudinale analyse bleek verder dat IADL beperkingen geassocieerd 
waren met meer depressieve symptomen op 90 jarige leeftijd. Daarbij bleek 
een snellere toename van beperkingen van de ADL en IADL geassocieerd te 
zijn met meer depressieve symptomen op 90 jarige leeftijd. Deze associaties 
waren onafhankelijk van cognitief functioneren en chronische ziekten. 
Opmerkelijk was de bevinding dat depressieve symptomen op 85 jarige leeftijd 
niet geassocieerd waren met toegenomen beperkingen in de dagelijkse levens-
verrichtingen tijdens follow-up. Het lijkt daarom van groot belang om functionele 
beperkingen in de dagelijkse levensverrichtingen actief op te sporen. Verder 
onderzoek is nodig om te kunnen vaststellen of revalidatie met als doel het 
functioneren te verbeteren ook een middel is om depressieve symptomen bij 
ouderen te voorkomen. 
11.4.4 De associatie tussen cognitieve functie en spierzwakte 
Cognitieve achteruitgang en spierzwakte zijn frequente en vaak tegelijkertijd 
bestaande aandoeningen bij oudere mensen. Het is onduidelijk wat de relatie 




achteruitgang en markeert spierzwakte daarom cognitieve achteruitgang of 
is er nu juist sprake van de omgekeerde relatie. In hoofdstuk 6 worden de 
resultaten beschreven van het onderzoek naar de relatie tussen deze aan -
doeningen. Geconcludeerd wordt dat een beter cognitief functioneren geassocieerd 
is met een betere handknijpkracht. Belangrijker nog is de bevinding dat in de 
longitudinale analyse beter cognitief functioneren, in het bijzonder executieve 
functies en geheugen, op 85 jarige leeftijd geassocieerd is met een beter behoud 
van de handknijpkracht na 4 jaar follow up. Verdere analyse kon geen relatie 
aantonen tussen slechte handknijpkracht en snellere cognitieve achteruitgang 
in de longitudinale analyse. Deze resultaten suggereren dat cognitieve achter -
uit gang vooraf gaat aan de ontwikkeling van spierzwakte. Dit betekent dat 
clinici bij het vaststellen van cognitieve stoornissen bij ouderen alert moeten 
zijn op het ontwikkelen van spierzwakte. Verder klinisch onderzoek is nodig om 
eventuele interventies te onderzoeken. 
11.5  Mogelijke determinanten van spierzwakte bij 
oudste oudere mensen
11.5.1 De associatie tussen bloeddruk en spierkracht
In hoofdstuk 7 worden de resultaten gepresenteerd van de longitudinale 
studie van de associatie tussen bloeddruk en handknijpkracht. De onderzoeks-
populaties bestonden uit oudste ouderen (Leiden 85-plus Studie) en deelnemers 
van middelbare leeftijd (Leiden Langleven Studie). Het onderzoek toonde aan 
dat hogere systolische- diastolische- en polsdrukken op 85 jarige leeftijd 
geassocieerd waren met een betere handknijpkracht. Verder bleek dat dalende 
systolische- diastolische- en polsdrukken geassocieerd waren met een afname 
van de handknijpkracht op 89 jarige leeftijd. Bij de deelnemers van middel - 
bare leeftijd was geen associatie tussen bloeddruk en handknijpkracht. De 
hypothese die verklaart waarom een hogere bloeddruk gunstig is op 85 jarige 
leeftijd wordt in dit hoofdstuk beschreven. De verklaring is mogelijk gelegen in 
het feit dat de perifere vaatweerstand tijdens de veroudering toeneemt en 
tegelijkertijd het vermogen tot vasodilatatie afneemt. Deze processen hebben 
tot gevolg dat hogere bloeddrukken noodzakelijk zijn voor het behoud van 
weefselperfusie in skeletspieren, zoals ook al eerder werd aangetoond voor 
cognitie en nierfunctie. Het is van belang dat verder onder- zoek moet 
plaatsvinden naar de gevolgen van hypertensie en de behandeling van hoge 
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bloeddruk bij oudste ouderen. Het is mogelijk dat winst op de cardiovasculaire 
eindpunten ten koste gaat van de spierkracht bij zeer oude mensen.
11.5.2  Insuline-achtige groeifactor-1 en spierkracht op middelbare 
en zeer hoge leeftijd 
De studie naar de relatie tussen insuline-achtige groeifactor-1 (IGF-1), IGF bin-
dingsproteïne 3 (IGFBP-3) en functionele prestatie op middelbare (62 jaar) en 
zeer hoge leeftijd (90 jaar) wordt beschreven in hoofdstuk 8. De serumconcen-
tratie van IGF-1 en bindingsproteïne, IGFBP-3 zijn beide lager op 90 jarige 
leeftijd. Verder bleek een hogere concentraties IGF-1 geassocieerd te zijn met 
betere handknijpkracht bij postmenopausale vrouwen van middelbare leeftijd. 
Op hoge leeftijd zijn hogere IGF-1 en IGFBP-3 serumconcentraties beide 
geassocieerd met een betere handknijpkracht. Bij mannen in beide leeftijds-
groepen werd deze relatie niet gevonden. Opmerkelijk is de bevinding dat bij 
zeer oude mannen een hogere serumconcentratie IGF-1 geassocieerd was met 
een slechtere prestatie op de looptest. Bij vrouwen bleek een hogere IGFBP-3 
serumconcentratie geassocieerd te zijn met beter ADL functioneren. Duidelijk 
is dat verder onderzoek naar mogelijke verklaringen van een mogelijk verschil 
tussen IGF-1 metabolisme bij mannen en vrouwen nodig is. Bij vrouwen is de 
leeftijd geassocieerde daling van groeihormoon en IGF-1 serumconcentraties 
een determinant van verlies van spiermassa en spierkracht en daarmee verhoogde 
kwetsbaarheid op hoge leeftijd. Het handhaven van hogere IGF-1 serumcon-
centraties is mogelijk een aangrijpingspunt om spierfunctie en prestaties bij 
oudere vrouwen te handhaven. 
11.5.3 De aangeboren cytokine productie capaciteit en spierzwakte 
Het doel van het onderzoek dat beschreven staat in hoofdstuk 9 was te 
onderzoeken of spierzwakte geassocieerd was met systemische inflammatie 
of met een aangeboren hoge pro-inflammatoire cytokine productie van Tumor 
Necrosis Factor-alpha (TNF-α). voor dit onderzoek werd de ex-vivo productie 
capaciteit van pro-inflammatoire en anti-inflammatoire cytokines bepaald. 
uit het onderzoek bleek dat systemische inflammatie niet geassocieerd was 
met spierzwakte. Wel bleek een hogere productie capaciteit van het pro- 
inflammatoire cytokine TNF-α geassocieerd te zijn met spierzwakte op 89 
jarige leeftijd. De associatie werd niet beïnvloed door andere cytokines. Dit 




bijdraagt aan spierzwakte bij oudste ouderen. Dit is niet geheel onverwacht 
omdat TNF-α, ooit genoemd ‘cachectin’ betrokken is bij inflammatie en apoptosis. 
11.6 Conclusies en toekomstig onderzoek
In dit onderzoek onder oudste ouderen is het functionele fenotype een sterke 
voorspeller van toekomstige functionele capaciteit en overleving. De resultaten 
van de studies beschreven in dit proefschrift scheppen verwachtingen over de 
voorspellende waarde van functionele meetinstrumenten bij oudste oudere 
patiënten in een klinische setting. Deze functionele meetinstrumenten zijn 
markers van vitaliteit en kunnen clinici attent maken op toekomstige gezond-
heidsproblemen bij hun zeer oude patiënten, zoals depressieve symptomen, 
cognitieve achteruitgang, beperkingen in ADL en mortaliteit. Daarbij kunnen 
deze markers van vitaliteit een hulpmiddel zijn bij de inschatting van prognose 
en daarmee samenhangende besluiten omtrent behandeling bij zeer oude 
patiënten die geconfronteerd worden met ernstige ziekten. Het is om die reden 
belangrijk dat de voorspellende waarde van handknijpkracht, loopsnelheid en 
IADL functioneren ook onderzocht wordt in klinische populaties van oudste 
oudere patiënten. 
Ten aanzien van mogelijke determinanten van spierzwakte bij oudste oudere 
mensen is de conclusie dat hoge bloeddruk geassocieerd is met hogere 
spierkracht zeer interessant. Van belang is dat hoge bloeddruk nu wederom 
geassocieerd werd met een gunstiger beloop bij oudste ouderen [25,27]. De 
vraag die dan beantwoord moet worden is of stringent behandelen van hogere 
bloeddrukken bij oudste ouderen nu wel zo gunstig is voor de spierkracht en 
zelfs succesvolle veroudering. 
De aangeboren productie capaciteit van TNF-α is ook een belangrijke determinant 
van spierzwakte bij oudste ouderen. Deze associatie wordt niet beïnvloed door 
chronische ziekte of productie capaciteit van andere cytokines. Dit is een 
belangrijke bevinding omdat de aangeboren productie capaciteit van cytokines 
een erfelijke eigenschap is [27]. Verder onderzoek is nodig om vast te stellen of 
dit resultaat ook in andere studies bij zeer oude mensen bevestigd wordt. Zo ja, 
dan zou interventie met anti TNF- α mogelijk een middel kunnen zijn om 
sarcopenie te voorkomen of behandelen bij ouderen met een verhoogd risico 
op deze aandoening. 
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Hogere serumwaardes van IGF-1 waren bij 90 jarige vrouwen geassocieerd 
met betere spierkracht, maar niet bij mannen. Dit suggereert een verschil 
tussen mannen en vrouwen met betrekking tot de IGF-1 gevoeligheid van 
spierweefsel. Een longitudinale studie is nodig om deze relatie verder te 
onderzoeken en antwoord te geven op de vraag of handhaving van IGF-1 
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